export type AntiarrhythmicClass = "Ia" | "Ib" | "Ic" | "II" | "III" | "IV";

export interface MedicationEntry {
  id: string;
  name: string;
  aliases: string[];
  drugClass: string;
  mechanism: string;
  indications: string[];
  adverseEffects: string[];
  boardsPearls: string[];
  antiarrhythmicClass?: AntiarrhythmicClass;
}

export const MEDICATIONS: MedicationEntry[] = [
  {
    id: "digoxin",
    name: "Digoxin",
    aliases: ["digoxin", "lanoxin"],
    drugClass: "Cardiac glycoside",
    mechanism:
      "Inhibits Na⁺/K⁺-ATPase → ↑ intracellular Ca²⁺ → positive inotropy; ↑ vagal tone → slows AV conduction.",
    indications: [
      "Symptomatic HFrEF",
      "Rate control in atrial fibrillation (especially with heart failure)",
    ],
    adverseEffects: [
      "Nausea, vomiting, anorexia",
      "Visual disturbances (yellow-green halos, blurred vision)",
      "Arrhythmias (PVCs, bradycardia, AV block, ventricular tachycardia)",
      "Narrow therapeutic window / toxicity",
    ],
    boardsPearls: [
      "Hypokalemia, hypomagnesemia, hypercalcemia, and renal failure increase toxicity",
      "Amiodarone, verapamil, and quinidine increase digoxin levels",
      "Toxicity antidote: digoxin-specific Fab fragments (binds free digoxin)",
    ],
  },
  {
    id: "furosemide",
    name: "Furosemide",
    aliases: ["furosemide", "lasix"],
    drugClass: "Loop diuretic",
    mechanism:
      "Inhibits Na⁺/K⁺/2Cl⁻ cotransporter in the thick ascending limb of the loop of Henle → potent natriuresis and diuresis.",
    indications: [
      "Acute pulmonary edema / volume overload",
      "Heart failure",
      "Edema (renal, hepatic, or cardiac)",
      "Hypertension (adjunct)",
    ],
    adverseEffects: [
      "Hypokalemia, hypomagnesemia, metabolic alkalosis",
      "Ototoxicity (especially with aminoglycosides)",
      "Dehydration, hypotension",
      "Hyperuricemia / gout",
    ],
    boardsPearls: [
      "Sulfonamide allergy: cross-reactivity possible but often still used cautiously",
      "Low ceiling effect compared with thiazides for HTN monotherapy",
      "Hypokalemia increases digoxin toxicity",
    ],
  },
  {
    id: "lisinopril",
    name: "Lisinopril",
    aliases: ["lisinopril"],
    drugClass: "ACE inhibitor",
    mechanism:
      "Blocks angiotensin-converting enzyme → ↓ angiotensin II and ↓ aldosterone → vasodilation, ↓ afterload, ↓ preload.",
    indications: [
      "Hypertension",
      "Heart failure (↓ mortality)",
      "Post-MI LV dysfunction",
      "Diabetic nephropathy",
    ],
    adverseEffects: [
      "Dry cough (bradykinin accumulation)",
      "Hyperkalemia",
      "Angioedema",
      "Teratogenic — contraindicated in pregnancy",
      "↑ creatinine / bilateral RAS can precipitate renal failure",
    ],
    boardsPearls: [
      "Contraindicated in pregnancy",
      "Avoid with bilateral renal artery stenosis",
      "Dry cough from bradykinin accumulation — ARBs do not inhibit kininase II",
    ],
  },
  {
    id: "enalapril",
    name: "Enalapril",
    aliases: ["enalapril"],
    drugClass: "ACE inhibitor",
    mechanism:
      "Prodrug converted to enalaprilat; inhibits ACE → ↓ angiotensin II and aldosterone → vasodilation and afterload reduction.",
    indications: [
      "Hypertension",
      "Heart failure",
      "Asymptomatic LV dysfunction",
    ],
    adverseEffects: [
      "Dry cough, hyperkalemia, angioedema",
      "Teratogenic — contraindicated in pregnancy",
      "Hypotension (first-dose effect)",
    ],
    boardsPearls: [
      "Same class pearls as other ACE inhibitors",
      "Prodrug requiring hepatic conversion (consider in liver disease)",
    ],
  },
  {
    id: "ace-inhibitors",
    name: "ACE inhibitors",
    aliases: [
      "ace inhibitors",
      "ace inhibitor",
      "acei",
      "ace-i",
      "angiotensin-converting enzyme inhibitors",
      "angiotensin converting enzyme inhibitors",
    ],
    drugClass: "Drug class",
    mechanism:
      "Block angiotensin-converting enzyme (kininase II) → ↓ angiotensin II and aldosterone → vasodilation, ↓ afterload, ↓ preload; ↑ bradykinin (cough, angioedema).",
    indications: [
      "Hypertension",
      "Heart failure (↓ mortality in HFrEF)",
      "Post-MI LV dysfunction",
      "Diabetic nephropathy / proteinuric CKD",
    ],
    adverseEffects: [
      "Dry cough (bradykinin)",
      "Hyperkalemia",
      "Angioedema",
      "Teratogenic — contraindicated in pregnancy",
      "↑ creatinine; bilateral renal artery stenosis → acute renal failure",
    ],
    boardsPearls: [
      "Examples: lisinopril, enalapril, captopril, ramipril",
      "Mortality benefit in HFrEF — cornerstone with β-blocker and MRA",
      "Contraindicated in pregnancy and bilateral renal artery stenosis",
      "Dry cough → switch to ARB (no kininase II inhibition)",
    ],
  },
  {
    id: "beta-blockers",
    name: "Beta blockers",
    aliases: [
      "beta blockers",
      "beta-blockers",
      "beta blocker",
      "beta-blocker",
      "β-blockers",
      "β blockers",
      "β-blocker",
      "bb",
    ],
    drugClass: "Drug class",
    mechanism:
      "Antagonize β-adrenergic receptors → ↓ heart rate, contractility, and renin release; reduce myocardial O₂ demand.",
    indications: [
      "Hypertension",
      "Angina",
      "Heart failure (chronic, stabilized HFrEF)",
      "Post-MI",
      "Rate control in atrial fibrillation",
      "Migraine prophylaxis, essential tremor (propranolol)",
    ],
    adverseEffects: [
      "Bradycardia, AV block, acute HF exacerbation",
      "Bronchospasm (especially nonselective agents)",
      "Masks hypoglycemia symptoms",
      "Fatigue, depression, impotence",
      "Rebound tachycardia/ischemia if withdrawn abruptly",
    ],
    boardsPearls: [
      "Examples: metoprolol, atenolol (β1-selective); propranolol (nonselective)",
      "Contraindicated in acute decompensated HF",
      "β1-selective preferred in asthma but still use caution",
      "Rate control in AF; avoid in WPW + AF (use procainamide instead)",
    ],
  },
  {
    id: "calcium-channel-blockers",
    name: "Calcium channel blockers",
    aliases: [
      "calcium channel blockers",
      "calcium channel blocker",
      "calcium-channel blockers",
      "calcium-channel blocker",
      "ccb",
      "ccbs",
    ],
    drugClass: "Drug class",
    mechanism:
      "Block L-type voltage-gated Ca²⁺ channels → reduced Ca²⁺ influx; effects depend on subclass (cardiac vs vascular selectivity).",
    indications: [
      "Hypertension",
      "Angina (stable and vasospastic)",
      "Rate control in AF/flutter (nondihydropyridines only)",
      "Supraventricular tachycardia (nondihydropyridines)",
    ],
    adverseEffects: [
      "Peripheral edema (especially dihydropyridines)",
      "Bradycardia and AV block (nondihydropyridines)",
      "Constipation (verapamil)",
      "Gingival hyperplasia",
      "Hypotension, reflex tachycardia (dihydropyridines)",
    ],
    boardsPearls: [
      "Two subclasses: dihydropyridines (vascular) vs nondihydropyridines (cardiac/AV nodal)",
      "Dihydropyridines: amlodipine, nifedipine — HTN/angina, not AV nodal rate control",
      "Nondihydropyridines: diltiazem, verapamil — rate control, AV nodal effects",
      "Avoid nondihydropyridine + β-blocker + digoxin combination (AV nodal depression)",
    ],
  },
  {
    id: "nondihydropyridine-calcium-channel-blockers",
    name: "Nondihydropyridine calcium channel blockers",
    aliases: [
      "nondihydropyridine calcium channel blockers",
      "nondihydropyridine calcium channel blocker",
      "nondihydropyridine ccb",
      "nondihydropyridine ccbs",
      "nondihydropyridine",
      "non-dihydropyridine calcium channel blocker",
      "non dihydropyridine ccb",
    ],
    drugClass: "Drug subclass",
    mechanism:
      "Block L-type Ca²⁺ channels in cardiac SA/AV node and vascular smooth muscle → ↓ AV nodal conduction and contractility; moderate vasodilation.",
    indications: [
      "Rate control in atrial fibrillation/flutter",
      "Supraventricular tachycardia",
      "Hypertension and angina",
    ],
    adverseEffects: [
      "Bradycardia, AV block, heart failure exacerbation",
      "Constipation (verapamil > diltiazem)",
      "Peripheral edema, hypotension",
      "Gingival hyperplasia (verapamil)",
    ],
    boardsPearls: [
      "Examples: diltiazem, verapamil (Class IV antiarrhythmics)",
      "Cardiac/AV nodal effects dominate — used for AF rate control",
      "Contraindicated in WPW + AF (shortens accessory pathway refractory period)",
      "Additive AV nodal depression with β-blockers and digoxin",
    ],
  },
  {
    id: "dihydropyridine-calcium-channel-blockers",
    name: "Dihydropyridine calcium channel blockers",
    aliases: [
      "dihydropyridine calcium channel blockers",
      "dihydropyridine calcium channel blocker",
      "dihydropyridine ccb",
      "dihydropyridine ccbs",
      "dihydropyridine",
      "dhp ccb",
    ],
    drugClass: "Drug subclass",
    mechanism:
      "Block L-type Ca²⁺ channels predominantly in vascular smooth muscle → arteriolar vasodilation with minimal direct SA/AV nodal depression.",
    indications: [
      "Hypertension",
      "Chronic stable angina",
      "Vasospastic (Prinzmetal) angina",
      "Raynaud phenomenon",
    ],
    adverseEffects: [
      "Peripheral edema (arteriolar dilation → ↑ capillary hydrostatic pressure)",
      "Flushing, headache, dizziness",
      "Reflex tachycardia (more with short-acting nifedipine)",
      "Gingival hyperplasia (nifedipine)",
    ],
    boardsPearls: [
      "Examples: amlodipine, nifedipine, felodipine, nicardipine",
      "Vascular selectivity — not first-line for AF rate control",
      "Peripheral edema often not fixed by diuretics alone",
      "Safer to combine with β-blockers than nondihydropyridines (less AV nodal depression)",
    ],
  },
  {
    id: "metoprolol",
    name: "Metoprolol",
    aliases: ["metoprolol", "lopressor"],
    drugClass: "Beta-1 selective blocker",
    mechanism:
      "Antagonizes β1 receptors → ↓ heart rate, contractility, and renin release; reduces myocardial O₂ demand.",
    indications: [
      "Hypertension",
      "Angina",
      "Heart failure (chronic, stabilized)",
      "Post-MI",
      "Rate control in atrial fibrillation",
    ],
    adverseEffects: [
      "Bradycardia, AV block, heart failure exacerbation (acute decompensated HF)",
      "Bronchospasm (less than nonselective β-blockers)",
      "Fatigue, depression, impotence",
      "Masks hypoglycemia symptoms",
    ],
    boardsPearls: [
      "Contraindicated in acute decompensated HF (↓ contractility worsens pump failure)",
      "Avoid abrupt withdrawal → rebound tachycardia / ischemia",
      "β1-selective but still use caution in asthma",
    ],
  },
  {
    id: "atenolol",
    name: "Atenolol",
    aliases: ["atenolol", "tenormin"],
    drugClass: "Beta-1 selective blocker",
    mechanism:
      "Antagonizes β1 receptors → ↓ heart rate, contractility, and renin release; hydrophilic β-blocker with minimal CNS penetration.",
    indications: [
      "Hypertension",
      "Angina",
      "Post-MI",
      "Rate control in atrial fibrillation",
    ],
    adverseEffects: [
      "Bradycardia, AV block, heart failure exacerbation (acute decompensated HF)",
      "Bronchospasm (less than nonselective β-blockers)",
      "Fatigue, cold extremities",
      "Masks hypoglycemia symptoms",
    ],
    boardsPearls: [
      "Hydrophilic β1-blocker — renally excreted; reduce dose in renal failure",
      "Less CNS side effects than lipophilic agents (propranolol, metoprolol)",
      "β1-selective but still use caution in asthma/COPD",
      "Avoid abrupt withdrawal → rebound tachycardia / ischemia",
    ],
  },
  {
    id: "amiodarone",
    name: "Amiodarone",
    aliases: ["amiodarone", "pacerone"],
    drugClass: "Class III antiarrhythmic (multichannel blocker)",
    antiarrhythmicClass: "III",
    mechanism:
      "Blocks K⁺, Na⁺, and Ca²⁺ channels and has noncompetitive β-blockade → prolongs action potential and refractory period.",
    indications: [
      "Ventricular arrhythmias",
      "Atrial fibrillation/flutter (rate and rhythm control)",
      "Refractory supraventricular tachycardias",
    ],
    adverseEffects: [
      "Pulmonary fibrosis / pneumonitis",
      "Hepatotoxicity, corneal microdeposits, photosensitivity",
      "Hypo- or hyperthyroidism",
      "QT prolongation, bradycardia, heart block",
      "Blue-gray skin discoloration (long-term)",
    ],
    boardsPearls: [
      "Many drug interactions via CYP inhibition; increases digoxin levels",
      "Contains iodine → thyroid dysfunction",
      "Long-term toxicities: pulmonary fibrosis, hepatotoxicity, corneal deposits, thyroid dysfunction",
    ],
  },
  {
    id: "adenosine",
    name: "Adenosine",
    aliases: ["adenosine", "adenocard"],
    drugClass: "Purine nucleoside / antiarrhythmic",
    mechanism:
      "Activates A1 receptors → ↑ K⁺ efflux → hyperpolarization and transient AV nodal block; very short half-life (seconds).",
    indications: [
      "Paroxysmal supraventricular tachycardia (AV nodal block)",
      "Diagnostic maneuver in wide-complex tachycardia (transient AV block)",
    ],
    adverseEffects: [
      "Transient flushing, chest discomfort, dyspnea",
      "Brief asystole or bradycardia (expected)",
      "Bronchospasm (use caution in asthma/COPD)",
    ],
    boardsPearls: [
      "Half-life ~10 seconds — terminated by RBC/endothelial uptake",
      "Ineffective orally or as slow infusion (degraded before reaching AV node)",
      "Methylxanthines (caffeine, theophylline) antagonize effect",
      "Pediatrics: same mechanism in SVT; blocked by methylxanthines",
    ],
  },
  {
    id: "diltiazem",
    name: "Diltiazem",
    aliases: ["diltiazem", "cardizem"],
    drugClass: "Class IV antiarrhythmic / nondihydropyridine calcium channel blocker",
    antiarrhythmicClass: "IV",
    mechanism:
      "Blocks L-type Ca²⁺ channels in cardiac SA/AV node and vascular smooth muscle → ↓ AV nodal conduction and contractility; peripheral vasodilation.",
    indications: [
      "Rate control in atrial fibrillation/flutter",
      "Supraventricular tachycardia",
      "Hypertension and angina",
    ],
    adverseEffects: [
      "Bradycardia, AV block, heart failure exacerbation",
      "Peripheral edema, constipation",
      "Hypotension",
      "Gingival hyperplasia (less common than verapamil)",
    ],
    boardsPearls: [
      "Nondihydropyridine CCB — cardiac effects dominate (vs amlodipine/nifedipine)",
      "Avoid with β-blockers or digoxin → additive AV nodal depression",
      "Contraindicated in WPW with AF (shortens refractory period in accessory pathway → ↑ ventricular rate)",
      "Pediatrics: same AV nodal effects; used cautiously for SVT rate control",
    ],
  },
  {
    id: "amlodipine",
    name: "Amlodipine",
    aliases: ["amlodipine", "norvasc"],
    drugClass: "Dihydropyridine calcium channel blocker",
    mechanism:
      "Blocks L-type Ca²⁺ channels in vascular smooth muscle → arteriolar vasodilation with minimal direct cardiac conduction effects (peripheral > cardiac selectivity).",
    indications: [
      "Hypertension",
      "Chronic stable angina",
      "Vasospastic (Prinzmetal) angina",
      "Coronary artery disease",
    ],
    adverseEffects: [
      "Peripheral edema (arteriolar dilation → capillary hydrostatic pressure)",
      "Flushing, headache, dizziness",
      "Reflex tachycardia (less than immediate-release nifedipine)",
      "Gingival hyperplasia (less common than nifedipine)",
    ],
    boardsPearls: [
      "Dihydropyridine CCB — vascular effects dominate (vs diltiazem/verapamil)",
      "Peripheral edema is common — not relieved by diuretics alone (arteriolar dilation mechanism)",
      "Does not significantly depress AV nodal conduction — safer with β-blockers than nondihydropyridines",
      "Long half-life → once-daily dosing",
    ],
  },
  {
    id: "nifedipine",
    name: "Nifedipine",
    aliases: ["nifedipine", "procardia", "adalat"],
    drugClass: "Dihydropyridine calcium channel blocker",
    mechanism:
      "Blocks L-type Ca²⁺ channels in vascular smooth muscle → potent arteriolar vasodilation; immediate-release formulation causes rapid hypotension and reflex tachycardia.",
    indications: [
      "Hypertension (extended-release preferred)",
      "Chronic stable angina",
      "Vasospastic (Prinzmetal) angina",
      "Raynaud phenomenon",
      "Tocolysis (acute preterm labor — specific formulations)",
    ],
    adverseEffects: [
      "Reflex tachycardia (especially immediate-release)",
      "Hypotension, flushing, headache",
      "Peripheral edema",
      "Gingival hyperplasia (classic association)",
    ],
    boardsPearls: [
      "Immediate-release nifedipine: avoid for HTN emergencies — unpredictable hypotension and reflex tachycardia",
      "Extended-release preferred for chronic HTN/angina",
      "Dihydropyridine CCB — not used for AF rate control (unlike diltiazem/verapamil)",
      "Gingival hyperplasia more common than with amlodipine",
    ],
  },
  {
    id: "procainamide",
    name: "Procainamide",
    aliases: ["procainamide", "pronestyl"],
    drugClass: "Class Ia antiarrhythmic",
    antiarrhythmicClass: "Ia",
    mechanism:
      "Blocks fast Na⁺ channels → moderate Na⁺ channel blockade, ↑ action potential duration and effective refractory period; active metabolite N-acetylprocainamide (NAPA) prolongs repolarization.",
    indications: [
      "Ventricular arrhythmias",
      "Supraventricular arrhythmias (atrial fibrillation/flutter, WPW)",
    ],
    adverseEffects: [
      "Drug-induced lupus (positive ANA, anti-histone antibodies)",
      "Hypotension (especially with IV loading)",
      "QT prolongation / torsades de pointes",
      "Agranulocytosis (rare)",
      "Negative inotropy",
    ],
    boardsPearls: [
      "Class Ia: moderate Na⁺ channel block + ↑ APD (quinidine-like)",
      "Classic drug-induced lupus — slow acetylators at higher risk; reversible on discontinuation",
      "NAPA metabolite has Class III–like repolarization effects",
      "Pediatrics: rarely used; lupus risk and hemodynamic effects limit routine use",
    ],
  },
  {
    id: "quinidine",
    name: "Quinidine",
    aliases: ["quinidine", "quinidex", "quinora"],
    drugClass: "Class Ia antiarrhythmic",
    antiarrhythmicClass: "Ia",
    mechanism:
      "Blocks fast Na⁺ channels and K⁺ channels → moderate Na⁺ blockade with ↑ action potential duration and effective refractory period; also α-adrenergic blockade.",
    indications: [
      "Atrial fibrillation/flutter (rhythm control)",
      "Ventricular arrhythmias",
      "Malaria (historical)",
    ],
    adverseEffects: [
      "Cinchonism (tinnitus, headache, nausea, blurred vision)",
      "QT prolongation / torsades de pointes",
      "Diarrhea (common — limits long-term use)",
      "Thrombocytopenia, hemolytic anemia",
      "Drug-induced lupus (less common than procainamide)",
    ],
    boardsPearls: [
      "Class Ia: moderate Na⁺ channel block + ↑ APD",
      "Increases digoxin levels — displaces digoxin from tissue binding and ↓ renal clearance",
      "Contraindicated in myasthenia gravis — worsens neuromuscular blockade",
      "Pediatrics: rarely first-line; cinchonism and GI intolerance limit use",
    ],
  },
  {
    id: "disopyramide",
    name: "Disopyramide",
    aliases: ["disopyramide", "norpace"],
    drugClass: "Class Ia antiarrhythmic",
    antiarrhythmicClass: "Ia",
    mechanism:
      "Blocks fast Na⁺ channels and has antimuscarinic activity → ↑ action potential duration and effective refractory period; negative inotropy.",
    indications: [
      "Ventricular arrhythmias",
      "Supraventricular arrhythmias (selected cases)",
    ],
    adverseEffects: [
      "Anticholinergic effects (dry mouth, urinary retention, constipation)",
      "Negative inotropy → heart failure exacerbation",
      "QT prolongation / torsades de pointes",
      "Hypoglycemia (especially in diabetics)",
    ],
    boardsPearls: [
      "Class Ia: moderate Na⁺ channel block + ↑ APD (quinidine-like)",
      "Strong anticholinergic and negative inotropic effects — avoid in HFrEF",
      "Use with caution in structural heart disease",
      "Pediatrics: rarely first-line; anticholinergic and inotropic effects limit use",
    ],
  },
  {
    id: "flecainide",
    name: "Flecainide",
    aliases: ["flecainide", "tambocor"],
    drugClass: "Class Ic antiarrhythmic",
    antiarrhythmicClass: "Ic",
    mechanism:
      "Strong block of fast Na⁺ channels → markedly slows conduction (↓ Vmax) with minimal effect on action potential duration.",
    indications: [
      "Supraventricular arrhythmias (including atrial fibrillation/flutter in structurally normal hearts)",
      "Life-threatening ventricular arrhythmias (selected patients without structural heart disease)",
    ],
    adverseEffects: [
      "Proarrhythmia (new or worsened ventricular arrhythmias)",
      "Bradycardia, heart block",
      "Dizziness, visual disturbances",
      "Negative inotropy",
    ],
    boardsPearls: [
      "Class Ic: strong Na⁺ block, minimal APD change — \"can organize\" AF into slow atrial flutter with 1:1 conduction",
      "Contraindicated in structural heart disease (post-MI, CAD, HFrEF) — CAST trial ↑ mortality",
      "Useful for rhythm control in lone AF with normal heart",
      "Pediatrics: reserved for refractory SVT in structurally normal hearts under specialist care",
    ],
  },
  {
    id: "propafenone",
    name: "Propafenone",
    aliases: ["propafenone", "rythmol"],
    drugClass: "Class Ic antiarrhythmic",
    antiarrhythmicClass: "Ic",
    mechanism:
      "Strong block of fast Na⁺ channels → markedly slows conduction (↓ Vmax) with minimal effect on action potential duration; weak β-adrenergic blockade.",
    indications: [
      "Supraventricular arrhythmias (including atrial fibrillation/flutter in structurally normal hearts)",
      "Ventricular arrhythmias (selected patients without structural heart disease)",
    ],
    adverseEffects: [
      "Proarrhythmia (new or worsened ventricular arrhythmias)",
      "Bradycardia, heart block",
      "Metallic taste, dizziness, nausea",
      "Negative inotropy",
      "Bronchospasm (weak β-blockade)",
    ],
    boardsPearls: [
      "Class Ic: strong Na⁺ block, minimal APD change — like flecainide",
      "Contraindicated in structural heart disease (CAD, post-MI, HFrEF) — proarrhythmia risk",
      "Intrinsic β-blocking activity — additive bradycardia with other nodal depressants",
      "Pediatrics: reserved for refractory SVT in structurally normal hearts under specialist care",
    ],
  },
  {
    id: "lidocaine",
    name: "Lidocaine",
    aliases: ["lidocaine", "xylocaine"],
    drugClass: "Class Ib antiarrhythmic / local anesthetic",
    antiarrhythmicClass: "Ib",
    mechanism:
      "Blocks fast Na⁺ channels preferentially in depolarized or ischemic tissue → shortens action potential duration; minimal effect on normal tissue.",
    indications: [
      "Ventricular arrhythmias (especially post-MI)",
      "Local/regional anesthesia",
    ],
    adverseEffects: [
      "CNS toxicity (perioral numbness, seizures, confusion)",
      "Cardiovascular depression at high doses",
      "Drowsiness, tinnitus",
    ],
    boardsPearls: [
      "Class Ib: preferentially binds inactivated Na⁺ channels in ischemic myocardium",
      "IV antiarrhythmic use largely replaced by amiodarone, but classic post-MI VT/VF drug",
      "CNS toxicity before cardiovascular collapse — perioral numbness is early warning",
      "Pediatrics: same ischemia-selective binding; toxicity risk ↑ with liver dysfunction",
    ],
  },
  {
    id: "mexiletine",
    name: "Mexiletine",
    aliases: ["mexiletine", "mexitil"],
    drugClass: "Class Ib antiarrhythmic",
    antiarrhythmicClass: "Ib",
    mechanism:
      "Blocks fast Na⁺ channels preferentially in depolarized or ischemic tissue → shortens action potential duration; oral analog of lidocaine.",
    indications: [
      "Ventricular arrhythmias (chronic oral therapy)",
      "Neuropathic pain (off-label)",
    ],
    adverseEffects: [
      "GI upset (nausea, vomiting)",
      "CNS effects (tremor, ataxia, dizziness, confusion)",
      "Bradycardia, heart block (less common)",
      "Hepatotoxicity (rare)",
    ],
    boardsPearls: [
      "Class Ib: preferentially binds inactivated Na⁺ channels — lidocaine-like but oral",
      "Useful for chronic oral suppression of ventricular arrhythmias when IV lidocaine is not practical",
      "CNS toxicity before cardiovascular collapse — dose-reduce in liver disease",
      "Pediatrics: rarely used; CNS and GI side effects limit routine use",
    ],
  },
  {
    id: "propranolol",
    name: "Propranolol",
    aliases: ["propranolol", "inderal"],
    drugClass: "Nonselective β-blocker (Class II antiarrhythmic)",
    antiarrhythmicClass: "II",
    mechanism:
      "Antagonizes β1 and β2 receptors → ↓ heart rate, contractility, and AV nodal conduction; ↓ renin release.",
    indications: [
      "Hypertension, angina, migraine prophylaxis",
      "Rate control in atrial fibrillation",
      "Thyrotoxicosis / thyroid storm",
      "Infantile hemangioma",
      "Essential tremor, performance anxiety",
    ],
    adverseEffects: [
      "Bronchospasm (β2 blockade)",
      "Bradycardia, AV block, heart failure exacerbation",
      "Masks hypoglycemia symptoms",
      "Fatigue, vivid dreams, impotence",
    ],
    boardsPearls: [
      "Nonselective β-blocker — avoid in asthma/COPD (unlike metoprolol/atenolol)",
      "Class II antiarrhythmic: ↓ cAMP → ↓ Ca²⁺ influx in nodal tissue",
      "Treats thyrotoxic symptoms (↓ peripheral T4→T3 conversion)",
      "Pediatrics: first-line for infantile hemangioma; bronchospasm risk limits use in reactive airway disease",
    ],
  },
  {
    id: "alteplase",
    name: "Alteplase",
    aliases: ["alteplase", "tpa", "t-pa", "activase"],
    drugClass: "Thrombolytic (tissue plasminogen activator)",
    mechanism:
      "Converts plasminogen to plasmin → fibrinolysis and clot dissolution.",
    indications: [
      "Acute ischemic stroke",
      "STEMI (fibrinolysis)",
      "Massive pulmonary embolism with hemodynamic instability",
    ],
    adverseEffects: [
      "Intracranial hemorrhage",
      "Systemic bleeding",
      "Reperfusion arrhythmias",
    ],
    boardsPearls: [
      "Contraindications: recent stroke/surgery, active bleeding, uncontrolled HTN",
      "Converts plasminogen → plasmin; major risk is intracranial hemorrhage",
      "Tenecteplase: modified tPA with longer half-life (fibrin-specific)",
    ],
  },
  {
    id: "atropine",
    name: "Atropine",
    aliases: ["atropine"],
    drugClass: "Antimuscarinic (anticholinergic)",
    mechanism:
      "Competitive muscarinic (M) receptor antagonist → blocks vagal effects on SA/AV node and smooth muscle.",
    indications: [
      "Symptomatic bradycardia",
      "Organophosphate/carbamate poisoning (with pralidoxime)",
      "Cycloplegia / mydriasis (ophthalmic)",
    ],
    adverseEffects: [
      "Tachycardia, dry mouth, urinary retention",
      "Confusion, hyperthermia (especially elderly)",
      "Mydriasis, acute angle-closure glaucoma risk",
      "Paradoxical bradycardia at low doses",
    ],
    boardsPearls: [
      "Muscarinic antagonist → ↑ HR via M2 blockade on SA/AV node",
      "Not effective for high-degree (type II second-degree or third-degree) AV block",
      "Organophosphate poisoning → atropine + pralidoxime (reactivates acetylcholinesterase)",
      "Pediatrics: bradycardia in infants often from hypoxia — address airway first",
    ],
  },
  {
    id: "morphine",
    name: "Morphine",
    aliases: ["morphine", "ms contin"],
    drugClass: "Opioid agonist (μ-receptor)",
    mechanism:
      "Agonist at μ-opioid receptors (and κ, δ) → ↑ analgesia, sedation, and respiratory depression; ↓ sympathetic outflow.",
    indications: [
      "Moderate to severe pain (acute and chronic)",
      "Acute pulmonary edema (reduces preload and sympathetic surge)",
      "Acute coronary syndrome / MI-related chest pain",
    ],
    adverseEffects: [
      "Respiratory depression",
      "Nausea, vomiting, constipation",
      "Miosis, sedation, urinary retention",
      "Hypotension and bradycardia",
      "Physical dependence and withdrawal",
    ],
    boardsPearls: [
      "Reversed by naloxone; shorter naloxone half-life → risk of renarcotization",
      "Avoid in severe asthma, COPD, or undiagnosed head injury (↑ CO₂ retention / ↑ ICP)",
      "Active metabolite morphine-6-glucuronide accumulates in renal failure → prolonged toxicity",
      "Pediatrics: respiratory depression is leading toxicity; same μ-receptor mechanism",
    ],
  },
  {
    id: "naloxone",
    name: "Naloxone",
    aliases: ["naloxone", "narcan"],
    drugClass: "Opioid antagonist",
    mechanism:
      "Competitive antagonist at μ, κ, and δ opioid receptors → reverses opioid-induced CNS and respiratory depression.",
    indications: [
      "Opioid overdose (respiratory depression, altered mental status)",
    ],
    adverseEffects: [
      "Acute opioid withdrawal (agitation, vomiting, diarrhea, tachycardia)",
      "Pulmonary edema (rare)",
      "Recurrent depression as naloxone wears off (shorter half-life than many opioids)",
    ],
    boardsPearls: [
      "Pinpoint pupils + ↓ respirations → opioid toxicity; competitive μ-receptor antagonist",
      "Shorter half-life than most opioids → renarcotization risk as naloxone wears off",
      "Precipitates acute withdrawal in opioid-dependent patients",
      "Pediatrics: same toxidrome; accidental ingestion or iatrogenic overdose",
    ],
  },
  {
    id: "physostigmine",
    name: "Physostigmine",
    aliases: ["physostigmine", "antilirium"],
    drugClass: "Reversible acetylcholinesterase inhibitor",
    mechanism:
      "Crosses blood-brain barrier; inhibits acetylcholinesterase → ↑ synaptic ACh at muscarinic and nicotinic sites.",
    indications: [
      "Anticholinergic (antimuscarinic) toxicity with CNS effects",
    ],
    adverseEffects: [
      "Bradycardia, salivation, bronchorrhea, seizures",
      "Cholinergic crisis if overdosed",
      "Contraindicated in TCA overdose (may worsen cardiac conduction)",
    ],
    boardsPearls: [
      "Antidote for pure anticholinergic toxidrome: hot as a hare, dry as a bone, mad as a hatter, blind as a bat",
      "Contraindicated in QRS widening / TCA ingestion — use sodium bicarbonate instead",
      "Atropine treats peripheral cholinergic excess; physostigmine treats central anticholinergic delirium",
      "Pediatrics: accidental diphenhydramine or scopolamine ingestion — same contraindications apply",
    ],
  },
  {
    id: "heparin",
    name: "Heparin",
    aliases: [
      "heparin",
      "unfractionated heparin",
      "ufh",
    ],
    drugClass: "Anticoagulant (indirect thrombin inhibitor)",
    mechanism:
      "Binds antithrombin III → markedly ↑ inhibition of factor Xa and thrombin (IIa).",
    indications: [
      "Acute venous thromboembolism",
      "Acute coronary syndromes",
      "Atrial fibrillation",
      "DIC (selected cases)",
    ],
    adverseEffects: [
      "Bleeding",
      "Heparin-induced thrombocytopenia (HIT)",
      "Osteoporosis (prolonged use)",
      "Hyperkalemia (suppressed aldosterone)",
    ],
    boardsPearls: [
      "Binds antithrombin III → potentiates inhibition of thrombin (IIa) and factor Xa",
      "HIT: immune-mediated anti-PF4 antibodies → thrombocytopenia + thrombosis",
      "Protamine sulfate reverses UFH (cationic protein binds acidic heparin)",
    ],
  },
  {
    id: "warfarin",
    name: "Warfarin",
    aliases: ["warfarin", "coumadin"],
    drugClass: "Vitamin K antagonist",
    mechanism:
      "Inhibits vitamin K epoxide reductase → impairs synthesis of factors II, VII, IX, X and proteins C & S.",
    indications: [
      "Atrial fibrillation (stroke prevention)",
      "Mechanical heart valves",
      "Venous thromboembolism treatment/prevention",
    ],
    adverseEffects: [
      "Bleeding",
      "Skin necrosis (protein C deficiency early on)",
      "Teratogenic — contraindicated in pregnancy",
    ],
    boardsPearls: [
      "Inhibits vitamin K epoxide reductase → ↓ factors II, VII, IX, X and protein C & S",
      "Narrow therapeutic window; vitamin K–rich foods and CYP2C9 inhibitors ↑ effect",
      "Skin necrosis early in therapy if congenital protein C deficiency",
      "Teratogenic — crosses placenta; fetal hemorrhage risk",
    ],
  },
  {
    id: "apixaban",
    name: "Apixaban",
    aliases: ["apixaban", "eliquis"],
    drugClass: "Direct factor Xa inhibitor (DOAC)",
    mechanism:
      "Directly inhibits factor Xa → ↓ thrombin generation without requiring antithrombin.",
    indications: [
      "Nonvalvular atrial fibrillation (stroke prevention)",
      "VTE treatment and prophylaxis",
    ],
    adverseEffects: [
      "Bleeding",
    ],
    boardsPearls: [
      "Direct factor Xa inhibitor — inhibits thrombin generation without antithrombin",
      "Contraindicated with mechanical heart valves (thrombosis risk)",
      "Renally cleared — accumulation risk with impaired kidney function",
    ],
  },
  {
    id: "rivaroxaban",
    name: "Rivaroxaban",
    aliases: ["rivaroxaban", "xarelto"],
    drugClass: "Direct factor Xa inhibitor (DOAC)",
    mechanism:
      "Directly inhibits factor Xa → ↓ thrombin generation without requiring antithrombin.",
    indications: [
      "Nonvalvular atrial fibrillation (stroke prevention)",
      "VTE treatment and prophylaxis (including post-orthopedic surgery)",
    ],
    adverseEffects: [
      "Bleeding",
      "GI upset",
    ],
    boardsPearls: [
      "Direct factor Xa inhibitor — once-daily dosing (food ↑ absorption)",
      "Contraindicated with mechanical heart valves",
      "Renally cleared — dose adjustment with impaired kidney function",
    ],
  },
  {
    id: "dabigatran",
    name: "Dabigatran",
    aliases: ["dabigatran", "pradaxa"],
    drugClass: "Direct thrombin inhibitor (DOAC)",
    mechanism:
      "Directly inhibits thrombin (factor IIa) → prevents fibrin formation.",
    indications: [
      "Nonvalvular atrial fibrillation (stroke prevention)",
      "VTE treatment",
    ],
    adverseEffects: [
      "Bleeding",
      "Dyspepsia",
    ],
    boardsPearls: [
      "Only oral direct thrombin inhibitor among DOACs",
      "Reversal agent: idarucizumab (Fab fragment)",
      "Contraindicated with mechanical heart valves",
    ],
  },
  {
    id: "lmwh",
    name: "Low-Molecular-Weight Heparin (LMWH)",
    aliases: [
      "lmwh",
      "low molecular weight heparin",
      "low-molecular-weight heparin",
      "low molecular weight heparins",
    ],
    drugClass: "Anticoagulant (indirect factor Xa inhibitor)",
    mechanism:
      "Short heparin chains bind antithrombin III → preferential inhibition of factor Xa over thrombin (higher anti-Xa:anti-IIa ratio than unfractionated heparin).",
    indications: [
      "VTE treatment and prophylaxis",
      "Acute coronary syndromes",
      "Bridging anticoagulation",
    ],
    adverseEffects: [
      "Bleeding",
      "Heparin-induced thrombocytopenia (less common than with UFH)",
      "Injection-site hematoma",
    ],
    boardsPearls: [
      "LMWH (e.g., enoxaparin, dalteparin) — mainly anti-Xa activity; subcutaneous, predictable PK",
      "Renally cleared — avoid or reduce dose if CrCl <30",
      "Protamine only partially reverses anti-Xa effect",
      "UFH inhibits Xa and IIa more equally; LMWH has less anti-IIa activity",
    ],
  },
  {
    id: "enoxaparin",
    name: "Enoxaparin",
    aliases: ["enoxaparin", "lovenox"],
    drugClass: "Low-molecular-weight heparin (LMWH)",
    mechanism:
      "Binds antithrombin III → preferentially inhibits factor Xa over thrombin (higher anti-Xa:anti-IIa ratio than UFH).",
    indications: [
      "VTE treatment and prophylaxis",
      "Acute coronary syndromes",
      "Bridging anticoagulation",
    ],
    adverseEffects: [
      "Bleeding",
      "Heparin-induced thrombocytopenia (HIT, less common than UFH)",
      "Injection-site hematoma",
    ],
    boardsPearls: [
      "LMWH — mainly anti-Xa activity; subcutaneous dosing, predictable PK (no routine monitoring)",
      "Renally cleared — avoid or reduce dose if CrCl <30",
      "Protamine partially reverses anti-Xa effect (less complete than for UFH)",
      "HIT still possible — switch to argatroban or fondaparinux if suspected",
    ],
  },
  {
    id: "fondaparinux",
    name: "Fondaparinux",
    aliases: ["fondaparinux", "arixtra"],
    drugClass: "Synthetic factor Xa inhibitor",
    mechanism:
      "Synthetic pentasaccharide that binds antithrombin III → selective factor Xa inhibition (no direct thrombin inhibition).",
    indications: [
      "VTE prophylaxis and treatment",
      "HIT (alternative anticoagulant when heparin contraindicated)",
    ],
    adverseEffects: [
      "Bleeding",
      "Injection-site reactions",
    ],
    boardsPearls: [
      "Synthetic pentasaccharide — selective anti-Xa without anti-IIa activity",
      "Safe in HIT (no PF4-heparin complex formation)",
      "Renally cleared — contraindicated if CrCl <30",
      "No protamine reversal — long half-life",
    ],
  },
  {
    id: "clopidogrel",
    name: "Clopidogrel",
    aliases: ["clopidogrel", "plavix"],
    drugClass: "P2Y12 ADP receptor antagonist (thienopyridine)",
    mechanism:
      "Irreversible P2Y12 ADP receptor blockade on platelets → ↓ GPIIb/IIIa activation and platelet aggregation.",
    indications: [
      "Acute coronary syndrome",
      "Post-PCI stent thrombosis prevention",
      "Secondary stroke prevention",
      "Peripheral arterial disease",
    ],
    adverseEffects: [
      "Bleeding",
      "Thrombotic thrombocytopenic purpura (rare)",
      "Rash, diarrhea",
    ],
    boardsPearls: [
      "Prodrug — requires CYP2C19 activation; poor metabolizers have ↓ efficacy",
      "Irreversible P2Y12 blockade — effect lasts platelet lifespan (~7–10 days)",
      "Combined with aspirin in ACS/PCI (dual antiplatelet therapy)",
      "Omeprazole may ↓ activation via CYP2C19 inhibition (clinical significance debated)",
    ],
  },
  {
    id: "ticagrelor",
    name: "Ticagrelor",
    aliases: ["ticagrelor", "brilinta"],
    drugClass: "P2Y12 ADP receptor antagonist (cyclopentyltriazolopyrimidine)",
    mechanism:
      "Reversible, noncompetitive P2Y12 ADP receptor blockade → ↓ platelet aggregation.",
    indications: [
      "Acute coronary syndrome",
      "Post-PCI (dual antiplatelet therapy with aspirin)",
    ],
    adverseEffects: [
      "Bleeding",
      "Dyspnea (common, usually benign)",
      "Bradycardia (transient)",
    ],
    boardsPearls: [
      "Reversible P2Y12 inhibitor — faster onset/offset than clopidogrel",
      "Active drug (not a prodrug) — no CYP2C19 dependence",
      "Twice-daily dosing; avoid >100 mg/day aspirin (↓ efficacy)",
    ],
  },
  {
    id: "prasugrel",
    name: "Prasugrel",
    aliases: ["prasugrel", "effient"],
    drugClass: "P2Y12 ADP receptor antagonist (thienopyridine)",
    mechanism:
      "Irreversible P2Y12 ADP receptor blockade → more potent and faster-acting than clopidogrel.",
    indications: [
      "Acute coronary syndrome undergoing PCI",
    ],
    adverseEffects: [
      "Bleeding (higher than clopidogrel)",
      "Thrombotic thrombocytopenic purpura (rare)",
    ],
    boardsPearls: [
      "More potent thienopyridine than clopidogrel — faster onset",
      "Contraindicated with prior stroke/TIA (↑ ICH risk)",
      "Contraindicated if age ≥75 or weight <60 kg (bleeding risk)",
    ],
  },
  {
    id: "eptifibatide",
    name: "Eptifibatide",
    aliases: ["eptifibatide", "integrilin"],
    drugClass: "Glycoprotein IIb/IIIa inhibitor",
    mechanism:
      "Blocks fibrinogen binding to GPIIb/IIIa receptor on activated platelets → inhibits final common pathway of platelet aggregation.",
    indications: [
      "High-risk ACS undergoing PCI",
      "PCI with glycoprotein IIb/IIIa inhibitor bailout",
    ],
    adverseEffects: [
      "Bleeding (major risk)",
      "Thrombocytopenia",
    ],
    boardsPearls: [
      "Blocks final common pathway of platelet aggregation (GPIIb/IIIa)",
      "IV use only — short half-life; used in cath lab setting",
      "Contraindicated with severe thrombocytopenia or active bleeding",
      "Abciximab and tirofiban are other GPIIb/IIIa inhibitors",
    ],
  },
  {
    id: "cilostazol",
    name: "Cilostazol",
    aliases: ["cilostazol", "pletal"],
    drugClass: "Phosphodiesterase-3 inhibitor / antiplatelet agent",
    mechanism:
      "Inhibits PDE-3 → ↑ cAMP in platelets and vascular smooth muscle → antiplatelet effect and vasodilation.",
    indications: [
      "Intermittent claudication (peripheral arterial disease)",
      "Secondary stroke prevention (selected patients)",
    ],
    adverseEffects: [
      "Headache, diarrhea, palpitations",
      "Contraindicated in heart failure (PDE-3 inhibitors ↑ mortality in HF)",
    ],
    boardsPearls: [
      "PDE-3 inhibitor — antiplatelet + vasodilator for claudication",
      "Contraindicated in heart failure (same class as milrinone — ↑ mortality)",
      "Improves walking distance in PAD; not first-line for ACS",
    ],
  },
  {
    id: "acetaminophen",
    name: "Acetaminophen",
    aliases: [
      "acetaminophen",
      "paracetamol",
      "tylenol",
      "apap",
      "n-acetyl-p-aminophenol",
    ],
    drugClass: "Analgesic / antipyretic",
    mechanism:
      "Centrally acting analgesic and antipyretic; inhibits prostaglandin synthesis in the CNS (weak peripheral COX inhibition). Exact mechanism incompletely defined — may involve COX-3, serotonergic pathways, and endocannabinoid system.",
    indications: [
      "Mild-to-moderate pain",
      "Fever",
      "Osteoarthritis (first-line analgesic when NSAIDs contraindicated)",
      "Preferred analgesic in pregnancy (short-term, therapeutic doses)",
    ],
    adverseEffects: [
      "Hepatotoxicity and acute liver failure in overdose (NAPQI metabolite depletes glutathione)",
      "Chronic high-dose use — hepatotoxicity even without single massive overdose",
      "Generally minimal GI, renal, and platelet effects at therapeutic doses",
    ],
    boardsPearls: [
      "Not an NSAID — no significant anti-inflammatory effect; does not inhibit platelet aggregation",
      "Overdose antidote: N-acetylcysteine (replenishes glutathione) — most effective within 8–10 h",
      "Max ~4 g/day in adults (lower in liver disease, alcohol use, malnutrition)",
      "Rumack-Matthew nomogram guides NAC treatment after acute ingestion",
      "vs ibuprofen — acetaminophen safer for GI/renal/platelet issues but hepatotoxic in overdose",
      "Peds: weight-based dosing; single most common cause of pediatric drug overdose",
    ],
  },
  {
    id: "nsaid",
    name: "NSAID",
    aliases: [
      "nsaid",
      "nsaids",
      "nonsteroidal anti-inflammatory drug",
      "nonsteroidal anti-inflammatory drugs",
      "non-steroidal anti-inflammatory drug",
    ],
    drugClass: "Nonsteroidal anti-inflammatory drug (NSAID)",
    mechanism:
      "Inhibits cyclooxygenase (COX) → ↓ prostaglandin and thromboxane A₂ synthesis → analgesic, antipyretic, anti-inflammatory effects; COX-1 inhibition also ↓ platelet aggregation and protects gastric mucosa.",
    indications: [
      "Pain, fever, inflammation (arthritis, dysmenorrhea, headache)",
      "Aspirin at low dose used for antiplatelet effect (irreversible COX-1 inhibition)",
    ],
    adverseEffects: [
      "GI bleeding and peptic ulcer disease (↓ protective PGE₂)",
      "Renal insufficiency (afferent arteriole vasoconstriction when prostaglandins blunted)",
      "Hypertension, fluid retention",
      "Cardiovascular thrombotic risk with chronic use (except low-dose aspirin)",
    ],
    boardsPearls: [
      "COX-1: platelets, gastric mucosa; COX-2: inflamed tissue — selective COX-2 inhibitors ↓ GI ulcer risk but ↑ CV risk",
      "Aspirin irreversibly acetylates COX-1; other NSAIDs reversibly inhibit COX",
      "NSAIDs ↓ renal blood flow — avoid in CKD, heart failure, dehydration",
      "Combine with PPI if GI risk; avoid NSAIDs in active PUD",
    ],
  },
  {
    id: "naproxen",
    name: "Naproxen",
    aliases: ["naproxen", "aleve", "naprosyn"],
    drugClass: "NSAID",
    mechanism:
      "Reversibly inhibits COX-1 and COX-2 → ↓ prostaglandin synthesis → analgesic, antipyretic, anti-inflammatory effects; COX-1 inhibition also ↓ thromboxane A₂.",
    indications: [
      "Pain, fever, inflammation (arthritis, dysmenorrhea)",
      "Not used as primary antiplatelet agent",
    ],
    adverseEffects: [
      "GI bleeding and peptic ulcer disease",
      "Renal insufficiency (afferent arteriole vasoconstriction)",
      "Hypertension, fluid retention",
      "Cardiovascular risk with chronic use",
    ],
    boardsPearls: [
      "NSAID — reversible COX inhibition (unlike aspirin’s irreversible COX-1 blockade)",
      "↑ cardiovascular thrombotic risk with chronic NSAID use",
      "Avoid in CKD, heart failure, active GI bleeding",
      "Pediatrics: avoid in dehydration (renal toxicity); not for fever in viral illness if aspirin alternatives preferred",
    ],
  },
  {
    id: "ibuprofen",
    name: "Ibuprofen",
    aliases: ["ibuprofen", "advil", "motrin", "nuprin"],
    drugClass: "NSAID",
    mechanism:
      "Reversibly inhibits COX-1 and COX-2 → ↓ prostaglandin and thromboxane A₂ synthesis → analgesic, antipyretic, and anti-inflammatory effects.",
    indications: [
      "Pain, fever, inflammation (arthritis, dysmenorrhea, headache)",
      "Acute gout flares (with colchicine or corticosteroids)",
      "Patent ductus arteriosus closure in premature infants",
      "Juvenile idiopathic arthritis",
    ],
    adverseEffects: [
      "GI bleeding and peptic ulcer disease",
      "Renal insufficiency (↓ prostaglandin-mediated afferent arteriole dilation)",
      "Hypertension, fluid retention",
      "Cardiovascular thrombotic risk with chronic use",
      "Aplastic anemia and interstitial nephritis (rare idiosyncratic)",
    ],
    boardsPearls: [
      "NSAID — anti-inflammatory unlike acetaminophen; reversible COX inhibition (unlike aspirin)",
      "First-line with colchicine/steroids for acute gout; also used to close PDA in prematurity",
      "Avoid in CKD, heart failure, active PUD, third trimester (ductus closure risk in fetus)",
      "vs acetaminophen — ibuprofen has GI/renal/platelet risks but anti-inflammatory for arthritis",
      "Peds: weight-based dosing; avoid in dehydration; do not confuse with aspirin (Reye syndrome)",
    ],
  },
  {
    id: "aspirin",
    name: "Aspirin",
    aliases: ["aspirin", "asa", "acetylsalicylic acid"],
    drugClass: "NSAID / antiplatelet agent",
    mechanism:
      "Irreversibly inhibits cyclooxygenase (COX-1 >> COX-2) → ↓ thromboxane A₂ synthesis → inhibits platelet aggregation; at higher doses also ↓ prostaglandins → analgesic, antipyretic, anti-inflammatory effects.",
    indications: [
      "Acute coronary syndrome (antiplatelet)",
      "Secondary prevention of MI, stroke, and cardiovascular events",
      "Kawasaki disease (with IVIG)",
      "Analgesia, fever, inflammation (higher doses)",
    ],
    adverseEffects: [
      "GI bleeding and peptic ulcer disease",
      "Bleeding (prolonged platelet dysfunction ~7–10 days)",
      "Tinnitus and salicylate toxicity (high doses)",
      "Reye syndrome in children with viral illness",
      "Asthma exacerbation (aspirin-exacerbated respiratory disease)",
    ],
    boardsPearls: [
      "Irreversible COX-1 inhibition → antiplatelet effect lasts platelet lifespan (~7–10 days)",
      "Contraindicated in children with febrile viral illness (Reye syndrome)",
      "Low-dose: antiplatelet; high-dose: analgesic/antipyretic/anti-inflammatory",
      "Pediatrics: avoid for fever in varicella/influenza; used in Kawasaki disease",
    ],
  },
  {
    id: "metformin",
    name: "Metformin",
    aliases: ["metformin"],
    drugClass: "Biguanide",
    mechanism:
      "↓ hepatic gluconeogenesis and improves peripheral insulin sensitivity; does not stimulate insulin secretion.",
    indications: [
      "Type 2 diabetes mellitus",
      "PCOS",
      "Prediabetes",
    ],
    adverseEffects: [
      "GI upset (nausea, diarrhea)",
      "Lactic acidosis (rare, especially with renal failure)",
      "Vitamin B12 deficiency (chronic use)",
    ],
    boardsPearls: [
      "↓ hepatic gluconeogenesis; does not stimulate insulin secretion",
      "Contraindicated in eGFR <30 (lactic acidosis risk)",
      "Does not cause hypoglycemia as monotherapy",
    ],
  },
  {
    id: "insulin",
    name: "Insulin",
    aliases: ["insulin"],
    drugClass: "Hormone / hypoglycemic agent",
    mechanism:
      "Binds insulin receptor → promotes glucose uptake, glycogenesis, lipogenesis; inhibits gluconeogenesis and lipolysis.",
    indications: [
      "Type 1 diabetes mellitus",
      "Type 2 diabetes (when oral agents insufficient)",
      "Hyperkalemia (with glucose)",
      "Diabetic ketoacidosis / hyperosmolar hyperglycemic state",
    ],
    adverseEffects: [
      "Hypoglycemia (most serious)",
      "Weight gain",
      "Lipohypertrophy at injection sites",
      "Hypokalemia (insulin drives K⁺ intracellularly during DKA correction)",
    ],
    boardsPearls: [
      "Drives K⁺ intracellularly — given with glucose for hyperkalemia",
      "β-blockers mask hypoglycemia symptoms (tachycardia, tremor)",
      "Formulations differ by onset and duration (rapid, NPH, glargine, etc.)",
    ],
  },
  {
    id: "insulin-glargine",
    name: "Insulin Glargine",
    aliases: [
      "insulin glargine",
      "glargine",
      "glargine insulin",
      "lantus",
      "basaglar",
    ],
    drugClass: "Long-acting insulin analog (basal)",
    mechanism:
      "Insulin analog with amino acid substitutions → forms microprecipitates at the injection site after subcutaneous administration → slow, prolonged absorption with relatively peakless basal insulin effect over ~24 hours.",
    indications: [
      "Basal glucose control in type 1 and type 2 diabetes mellitus",
      "Once-daily background insulin paired with prandial rapid-acting insulin or oral agents",
    ],
    adverseEffects: [
      "Hypoglycemia (especially nocturnal if dose excessive)",
      "Weight gain",
      "Injection-site reactions and lipohypertrophy",
    ],
    boardsPearls: [
      "Long-acting basal insulin — once daily, relatively peakless profile (~24 h duration)",
      "vs NPH — glargine has flatter pharmacokinetics; NPH has more pronounced peak and often BID dosing",
      "vs rapid insulin (lispro, aspart) — glargine is basal, not meal-time",
      "Do not mix with other insulins in the same syringe",
      "Peds: basal insulin in type 1 diabetes; same hypoglycemia precautions and weight-based dosing",
    ],
  },
  {
    id: "levothyroxine",
    name: "Levothyroxine",
    aliases: ["levothyroxine", "synthroid"],
    drugClass: "Synthetic T4 (thyroid hormone)",
    mechanism:
      "Peripheral conversion to T3 → binds nuclear receptors → regulates metabolic gene transcription.",
    indications: [
      "Hypothyroidism",
      "Thyroid cancer suppression therapy",
      "Myxedema coma",
    ],
    adverseEffects: [
      "Symptoms of hyperthyroidism if overdosed (palpitations, weight loss, heat intolerance)",
      "Atrial fibrillation in elderly if over-replaced",
    ],
    boardsPearls: [
      "T4 prodrug → peripheral conversion to active T3",
      "Many drug interactions (Ca²⁺, Fe, PPIs ↓ absorption)",
      "Pregnancy ↑ thyroid hormone requirements; TSH guides adequacy",
    ],
  },
  {
    id: "prednisone",
    name: "Prednisone",
    aliases: ["prednisone"],
    drugClass: "Glucocorticoid",
    mechanism:
      "Binds glucocorticoid receptor → alters gene transcription → anti-inflammatory, immunosuppressive, and metabolic effects.",
    indications: [
      "Autoimmune and inflammatory disorders",
      "Asthma/COPD exacerbations",
      "Adrenal insufficiency",
      "Transplant rejection",
      "Allergic reactions",
    ],
    adverseEffects: [
      "Cushingoid features, hyperglycemia, hypertension",
      "Osteoporosis, avascular necrosis",
      "Immunosuppression, poor wound healing",
      "Adrenal suppression with prolonged use",
    ],
    boardsPearls: [
      "Taper after chronic use to avoid adrenal crisis",
      "Worsens infections; can mask fever",
      "Hyperglycemia and psychosis are classic acute effects",
    ],
  },
  {
    id: "corticosteroids",
    name: "Corticosteroids",
    aliases: [
      "corticosteroid",
      "corticosteroids",
      "glucocorticoid",
      "glucocorticoids",
      "systemic corticosteroids",
      "systemic glucocorticoids",
    ],
    drugClass: "Drug class",
    mechanism:
      "Bind intracellular glucocorticoid receptor → translocate to nucleus → alter gene transcription → ↓ inflammatory cytokines (IL-1, IL-6, TNF-α), ↓ phospholipase A₂, stabilize lysosomal membranes, ↓ leukocyte migration, and suppress cell-mediated immunity.",
    indications: [
      "Autoimmune and inflammatory diseases (RA, lupus, IBD, vasculitis)",
      "Asthma/COPD exacerbations; allergic reactions",
      "Adrenal insufficiency replacement (hydrocortisone)",
      "Transplant rejection and immunosuppression (with calcineurin inhibitors)",
      "Cerebral edema (dexamethasone); croup, preterm lung maturity (dexamethasone)",
      "Inhaled corticosteroids — chronic asthma maintenance (fluticasone, budesonide)",
    ],
    adverseEffects: [
      "Cushingoid facies, moon facies, buffalo hump, striae, weight gain",
      "Hyperglycemia, hypertension, hypokalemia, osteoporosis, avascular necrosis",
      "Immunosuppression, impaired wound healing, cataracts, glaucoma",
      "Adrenal suppression (HPA axis) with chronic use — adrenal crisis if stopped abruptly",
      "Psychiatric effects (mania, psychosis), mood changes",
      "Peptic ulcer disease risk (especially with NSAIDs)",
    ],
    boardsPearls: [
      "Examples: hydrocortisone (most mineralocorticoid activity), prednisone/prednisolone, methylprednisolone, dexamethasone (most potent, no mineralocorticoid activity)",
      "Taper after >2–3 weeks chronic use — exogenous steroids suppress ACTH → adrenal atrophy",
      "Stress-dose steroids needed perioperatively if chronic use (prevent adrenal crisis)",
      "Inhaled/topical forms ↓ systemic side effects but still suppress HPA at high doses",
      "Dexamethasone crosses BBB well — cerebral edema, meningitis adjunct",
      "vs anabolic androgens — corticosteroids are anti-inflammatory glucocorticoids, not testosterone analogs",
    ],
  },
  {
    id: "methotrexate",
    name: "Methotrexate",
    aliases: ["methotrexate", "mtx", "amethopterin"],
    drugClass: "Antimetabolite / DMARD",
    mechanism:
      "Folic acid analog that inhibits dihydrofolate reductase → ↓ tetrahydrofolate → impaired purine and thymidine synthesis → ↓ DNA synthesis in rapidly dividing cells; at low weekly doses in RA, also has adenosine-mediated anti-inflammatory effects.",
    indications: [
      "Rheumatoid arthritis and psoriatic arthritis (anchor DMARD)",
      "Psoriasis",
      "Inflammatory bowel disease (Crohn disease, ulcerative colitis)",
      "Ectopic pregnancy (with misoprostol)",
      "ALL maintenance therapy; gestational trophoblastic disease",
      "Mycosis fungoides / cutaneous T-cell lymphoma (low-dose weekly)",
    ],
    adverseEffects: [
      "Myelosuppression (leukopenia, thrombocytopenia)",
      "Hepatotoxicity (fibrosis/cirrhosis with chronic use)",
      "Stomatitis, mucositis, nausea",
      "Pulmonary fibrosis / pneumonitis",
      "Teratogenic — absolute contraindication in pregnancy",
    ],
    boardsPearls: [
      "Weekly dosing in RA/psoriasis — daily dosing is for oncology; confusion is a classic error",
      "Supplement folic acid (or folinic acid rescue in high-dose oncology) to reduce toxicity",
      "Monitor CBC and LFTs; avoid alcohol; teratogenic — contraception required",
      "Co-therapy with anti-TNF biologics ↓ anti-drug antibody formation and improves durability",
      "Ectopic pregnancy: methotrexate IM if stable, low β-hCG, unruptured",
    ],
  },
  {
    id: "hydroxychloroquine",
    name: "Hydroxychloroquine",
    aliases: [
      "hydroxychloroquine",
      "hcq",
      "plaquenil",
      "hydroxychloroquin",
    ],
    drugClass: "Antimalarial / DMARD",
    mechanism:
      "Weak base accumulates in lysosomes → ↑ lysosomal pH → ↓ antigen processing and TLR signaling; also accumulates in melanin-rich tissues and may ↓ UV-driven inflammation.",
    indications: [
      "Systemic lupus erythematosus (maintenance, skin/joint disease)",
      "Rheumatoid arthritis",
      "Sjögren syndrome",
      "Malaria prophylaxis and treatment (less preferred than chloroquine where sensitive)",
    ],
    adverseEffects: [
      "Retinopathy with bull's-eye maculopathy (irreversible)",
      "Pruritus (especially in darker skin tones)",
      "Myopathy and cardiomyopathy (rare)",
      "GI upset, headache",
      "Hemolysis in G6PD deficiency",
    ],
    boardsPearls: [
      "Baseline and annual ophthalmologic screening for retinopathy — high-yield SLE drug",
      "Antimalarial DMARD — cornerstone of SLE maintenance; also treats joint and cutaneous lupus",
      "QT prolongation — caution with other QT-prolonging drugs",
      "vs chloroquine — hydroxychloroquine has less retinal toxicity but still requires eye exams",
      "Peds: used in juvenile SLE; same retinopathy monitoring; weight-based dosing",
    ],
  },
  {
    id: "sulfasalazine",
    name: "Sulfasalazine",
    aliases: ["sulfasalazine", "sulphasalazine", "azulfidine"],
    drugClass: "5-ASA / sulfa DMARD",
    mechanism:
      "Colonic bacteria cleave azo bond → releases 5-aminosalicylic acid (mesalamine, topical gut anti-inflammatory) and sulfapyridine; in RA, sulfapyridine moiety may have anti-inflammatory/DMARD effects (exact mechanism incompletely defined).",
    indications: [
      "Ulcerative colitis (induction and maintenance)",
      "Crohn colitis",
      "Rheumatoid arthritis",
    ],
    adverseEffects: [
      "GI upset, nausea, headache",
      "Orange discoloration of urine and tears",
      "Reversible oligospermia",
      "Hypersensitivity rash (sulfa moiety)",
      "Bone marrow suppression, hepatotoxicity (rare)",
    ],
    boardsPearls: [
      "UC maintenance drug — 5-ASA released in colon after bacterial cleavage",
      "Sulfa component → caution in sulfa allergy and G6PD deficiency (hemolysis)",
      "Interferes with folate absorption — supplement folic acid in RA",
      "Orange body fluids are benign but classic boards detail",
      "vs mesalamine — sulfasalazine includes sulfa carrier; mesalamine is 5-ASA alone",
    ],
  },
  {
    id: "colchicine",
    name: "Colchicine",
    aliases: ["colchicine"],
    drugClass: "Antigout / anti-inflammatory",
    mechanism:
      "Binds β-tubulin → inhibits microtubule polymerization in neutrophils → ↓ chemotaxis, phagocytosis, and inflammasome activation; blocks urate crystal–induced inflammation.",
    indications: [
      "Acute gout flares",
      "Gout flare prophylaxis when initiating urate-lowering therapy",
      "Familial Mediterranean fever",
      "Recurrent pericarditis",
    ],
    adverseEffects: [
      "Diarrhea, nausea, vomiting (common; dose-limiting)",
      "Myelosuppression and hepatotoxicity at toxic doses",
      "Myopathy and rhabdomyolysis (especially with statins or CYP3A4/P-gp inhibitors)",
      "Peripheral neuropathy with chronic toxicity",
    ],
    boardsPearls: [
      "Acute gout: colchicine, NSAIDs, or corticosteroids — start within 12–24 h of flare for best effect",
      "Narrow therapeutic window — diarrhea often precedes serious toxicity",
      "Drug interactions: strong CYP3A4 inhibitors (azole antifungals, macrolides) and P-gp inhibitors ↑ toxicity",
      "Do not use in severe renal or hepatic impairment without dose adjustment",
      "vs allopurinol/febuxostat — colchicine treats flare, does not lower uric acid",
    ],
  },
  {
    id: "minocycline",
    name: "Minocycline",
    aliases: ["minocycline", "minocin"],
    drugClass: "Tetracycline antibiotic / DMARD",
    mechanism:
      "Binds 30S ribosomal subunit → ↓ bacterial protein synthesis; in RA, additional anti-inflammatory effects (↓ metalloproteinases, neutrophil function) independent of antimicrobial activity.",
    indications: [
      "Acne vulgaris",
      "Rheumatoid arthritis (DMARD adjunct)",
      "Lyme disease, rickettsial infections",
      "MRSA skin infections (community-acquired)",
      "Nocardia and atypical mycobacteria (specialist use)",
    ],
    adverseEffects: [
      "Blue-gray hyperpigmentation (skin, nails, sclera, teeth)",
      "Drug-induced lupus (anti-histone antibodies; usually resolves after stopping)",
      "Vestibular toxicity (dizziness, ataxia)",
      "Hepatotoxicity, autoimmune hepatitis (rare)",
      "Photosensitivity; pseudotumor cerebri (like other tetracyclines)",
    ],
    boardsPearls: [
      "Tetracycline class — contraindicated in pregnancy and children <8 (teeth discoloration, bone growth inhibition)",
      "Drug-induced lupus from minocycline — positive anti-histone, negative anti-dsDNA typically",
      "Hyperpigmentation is classic minocycline-specific adverse effect",
      "vs doxycycline — minocycline more vestibular toxicity and pigmentation; better MRSA skin coverage",
      "RA: used as DMARD when conventional agents contraindicated or as adjunct",
    ],
  },
  {
    id: "haloperidol",
    name: "Haloperidol",
    aliases: ["haloperidol", "haldol"],
    drugClass: "Typical (first-generation) antipsychotic",
    mechanism:
      "Dopamine D2 receptor antagonism in mesolimbic pathway → ↓ positive psychotic symptoms.",
    indications: [
      "Schizophrenia",
      "Acute agitation / psychosis",
      "Tourette syndrome",
      "Severe nausea/vomiting",
    ],
    adverseEffects: [
      "Extrapyramidal symptoms (dystonia, akathisia, parkinsonism, tardive dyskinesia)",
      "Hyperprolactinemia",
      "QT prolongation",
      "Neuroleptic malignant syndrome",
    ],
    boardsPearls: [
      "High-potency typical antipsychotic → more EPS, less sedation/anticholinergic effects",
      "NMS: rigidity, fever, autonomic instability, ↑ CK — dopamine blockade toxicity",
      "Avoid in Lewy body dementia (severe sensitivity)",
    ],
  },
  {
    id: "lorazepam",
    name: "Lorazepam",
    aliases: ["lorazepam", "ativan"],
    drugClass: "Benzodiazepine",
    mechanism:
      "Enhances GABA-A receptor activity → ↑ Cl⁻ influx → neuronal hyperpolarization and CNS depression.",
    indications: [
      "Anxiety",
      "Alcohol withdrawal",
      "Status epilepticus",
      "Preprocedure sedation",
    ],
    adverseEffects: [
      "Sedation, confusion (especially elderly)",
      "Respiratory depression (with opioids)",
      "Dependence and withdrawal",
      "Ataxia",
    ],
    boardsPearls: [
      "Alcohol withdrawal: GABA facilitation prevents seizures and delirium tremens",
      "Flumazenil reverses overdose but may precipitate seizures",
      "Avoid combining with alcohol/opioids",
    ],
  },
  {
    id: "fluoxetine",
    name: "Fluoxetine",
    aliases: ["fluoxetine", "prozac"],
    drugClass: "SSRI",
    mechanism:
      "Selectively inhibits presynaptic serotonin reuptake → ↑ synaptic 5-HT.",
    indications: [
      "Major depressive disorder",
      "OCD, panic disorder, bulimia nervosa",
      "PTSD",
    ],
    adverseEffects: [
      "GI upset, sexual dysfunction, insomnia",
      "Serotonin syndrome (with MAOIs, other serotonergic drugs)",
      "Bleeding risk (↓ platelet serotonin)",
      "Activation / increased suicidality in young adults (early treatment)",
    ],
    boardsPearls: [
      "Long half-life (active metabolite norfluoxetine)",
      "Do not combine with MAOIs",
      "Serotonin syndrome: hyperthermia, clonus, agitation, autonomic instability",
    ],
  },
  {
    id: "gentamicin",
    name: "Gentamicin",
    aliases: ["gentamicin"],
    drugClass: "Aminoglycoside antibiotic",
    mechanism:
      "Binds 30S ribosomal subunit → misreading of mRNA → bactericidal against aerobic Gram-negative rods.",
    indications: [
      "Serious Gram-negative infections (often combined with β-lactam)",
      "Endocarditis (synergy with cell-wall agents)",
      "Uncomplicated UTI (selected cases)",
    ],
    adverseEffects: [
      "Nephrotoxicity",
      "Ototoxicity (vestibular and cochlear)",
      "Neuromuscular blockade",
    ],
    boardsPearls: [
      "Binds 30S ribosomal subunit → misreading of mRNA (concentration-dependent killing)",
      "Synergistic with β-lactams for enterococcal endocarditis (cell-wall + protein synthesis)",
      "Nephrotoxic and ototoxic — risk ↑ with loop diuretics and vancomycin",
    ],
  },
  {
    id: "vancomycin",
    name: "Vancomycin",
    aliases: ["vancomycin"],
    drugClass: "Glycopeptide antibiotic",
    mechanism:
      "Inhibits cell wall peptidoglycan polymerization by binding D-Ala-D-Ala → bactericidal against Gram-positive cocci.",
    indications: [
      "MRSA infections",
      "Serious Gram-positive infections (endocarditis, meningitis)",
      "C. difficile colitis (oral formulation)",
    ],
    adverseEffects: [
      "Nephrotoxicity",
      "Red man syndrome (rapid infusion — histamine release)",
      "Ototoxicity",
      "Thrombophlebitis",
    ],
    boardsPearls: [
      "Binds D-Ala-D-Ala → inhibits peptidoglycan polymerization (Gram-positive)",
      "Red man syndrome from rapid infusion (histamine release, not true allergy)",
      "Oral vancomycin not absorbed — treats C. difficile in gut lumen only",
    ],
  },
  {
    id: "sildenafil",
    name: "Sildenafil",
    aliases: [
      "sildenafil",
      "viagra",
      "revatio",
      "phosphodiesterase type 5 inhibitor",
      "phosphodiesterase-5 inhibitor",
      "phosphodiesterase 5 inhibitor",
      "pde-5 inhibitor",
      "pde5 inhibitor",
    ],
    drugClass: "Phosphodiesterase type 5 (PDE-5) inhibitor",
    mechanism:
      "Inhibits PDE-5 → prevents cGMP degradation → ↑ cGMP in vascular smooth muscle → vasodilation (systemic and pulmonary).",
    indications: [
      "Erectile dysfunction",
      "Pulmonary arterial hypertension (PAH)",
    ],
    adverseEffects: [
      "Headache, flushing, dyspepsia",
      "Hypotension (especially with nitrates or α-blockers)",
      "Visual disturbances (blue tinge; PDE-6 cross-reactivity in retina)",
      "Priapism (rare)",
    ],
    boardsPearls: [
      "Absolute contraindication with nitrates (e.g., nitroglycerin) → life-threatening hypotension",
      "Also inhibits PDE-6 in retina → blue-tinged vision",
      "Metabolized by CYP3A4 — levels ↑ with ritonavir and grapefruit",
      "Same drug as Revatio; PAH dosing differs from erectile dysfunction dosing",
      "Pediatrics: approved for PAH in children ≥1 year (weight-based dosing)",
    ],
  },
  {
    id: "tmp-smx",
    name: "Trimethoprim-Sulfamethoxazole",
    aliases: [
      "trimethoprim-sulfamethoxazole",
      "tmp-smx",
      "tmp/smx",
      "bactrim",
      "septra",
    ],
    drugClass: "Sulfonamide + folate synthesis inhibitor",
    mechanism:
      "Sulfamethoxazole inhibits dihydropteroate synthase; trimethoprim inhibits dihydrofolate reductase → blocks bacterial folate synthesis.",
    indications: [
      "Uncomplicated UTI",
      "Pneumocystis jirovecii pneumonia (prophylaxis and treatment)",
      "MRSA skin infections (community)",
      "Toxoplasmosis prophylaxis",
    ],
    adverseEffects: [
      "Hyperkalemia (trimethoprim blocks ENaC)",
      "Stevens-Johnson syndrome / TEN",
      "Hemolytic anemia in G6PD deficiency",
      "Crystalluria, nephrotoxicity",
    ],
    boardsPearls: [
      "Avoid in third trimester and near term (kernicterus risk)",
      "Classic cause of hyperkalemia in elderly",
      "Increase warfarin effect",
    ],
  },
  {
    id: "tacrolimus",
    name: "Tacrolimus",
    aliases: ["tacrolimus", "fk506", "prograf", "advagraf", "astagraf"],
    drugClass: "Calcineurin inhibitor (immunosuppressant)",
    mechanism:
      "Binds FKBP-12 → inhibits calcineurin → blocks NFAT dephosphorylation → ↓ IL-2 transcription → ↓ T-cell activation and proliferation.",
    indications: [
      "Solid organ transplant rejection prophylaxis (kidney, liver, heart, lung)",
      "Topical formulation for atopic dermatitis (lower systemic exposure)",
      "Steroid-sparing immunosuppression in some autoimmune diseases",
    ],
    adverseEffects: [
      "Nephrotoxicity (vasoconstriction, acute and chronic kidney injury)",
      "Neurotoxicity (tremor, headache, posterior reversible encephalopathy syndrome)",
      "Hyperglycemia / new-onset diabetes after transplant",
      "Hypertension, hyperkalemia, hypomagnesemia",
      "Increased infection and malignancy risk (EBV → PTLD)",
    ],
    boardsPearls: [
      "Calcineurin inhibitor — same pathway as cyclosporine; tacrolimus more potent",
      "Monitor trough levels; nephrotoxicity is dose- and level-dependent",
      "CYP3A4 substrate — levels ↑ with azoles, macrolides, grapefruit; ↓ with rifampin",
      "vs cyclosporine — both inhibit calcineurin; tacrolimus more commonly used in modern transplant regimens",
      "Peds: used in pediatric transplant; growth and infection monitoring essential",
    ],
  },
  {
    id: "rituximab",
    name: "Rituximab",
    aliases: ["rituximab", "rituxan", "mabthera"],
    drugClass: "Anti-CD20 monoclonal antibody",
    mechanism:
      "Chimeric monoclonal antibody against CD20 on B cells → complement- and antibody-mediated B-cell depletion → ↓ autoantibody production and malignant B-cell burden.",
    indications: [
      "CD20⁺ non-Hodgkin lymphoma and CLL",
      "Rheumatoid arthritis (TNF-inhibitor refractory)",
      "ANCA-associated vasculitis (alternative to cyclophosphamide for induction)",
      "Autoimmune hemolytic anemia and ITP (refractory)",
      "Post-transplant lymphoproliferative disorder (PTLD)",
      "Pemphigus vulgaris and other antibody-mediated autoimmune diseases",
    ],
    adverseEffects: [
      "Infusion reactions (fever, rigors, hypotension — premedicate)",
      "Reactivation of hepatitis B and other latent infections",
      "Progressive multifocal leukoencephalopathy (PML) with prolonged immunosuppression",
      "Hypogammaglobulinemia and recurrent infections",
      "Tumor lysis syndrome (high tumor burden lymphomas)",
    ],
    boardsPearls: [
      "Anti-CD20 → depletes B cells; does not affect plasma cells (already differentiated)",
      "ANCA vasculitis — rituximab noninferior to cyclophosphamide for induction",
      "Screen for hepatitis B before use; HBV reactivation can be fatal",
      "PTLD (EBV-driven) — reduce immunosuppression ± rituximab",
      "Peds: used in refractory pediatric autoimmune cytopenias and CD20⁺ lymphomas; live vaccines contraindicated during and after therapy",
    ],
  },
  {
    id: "ivig",
    name: "IVIG",
    aliases: [
      "ivig",
      "iv ig",
      "intravenous immunoglobulin",
      "intravenous immune globulin",
      "immune globulin intravenous",
      "iv immune globulin",
      "pooled immunoglobulin",
      "gamma globulin infusion",
      "iv gamma globulin",
    ],
    drugClass: "Immune globulin / immunomodulatory biologic",
    mechanism:
      "Pooled polyclonal human IgG from thousands of donors — replaces deficient antibody (replacement therapy) and modulates immunity by saturating Fc receptors on macrophages, neutralizing autoantibodies, inhibiting complement, and altering cytokine networks (exact mechanism varies by disease).",
    indications: [
      "Kawasaki disease (with aspirin) — ↓ coronary aneurysm risk when given within 10 days of fever onset",
      "Immune thrombocytopenia (ITP) — rapid ↑ platelet count",
      "Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy (CIDP)",
      "Myasthenia gravis exacerbation",
      "Common variable immunodeficiency (CVID) and other hypogammaglobulinemia (IgG replacement)",
      "Autoimmune hemolytic anemia (refractory)",
      "Toxic epidermal necrolysis (supportive, controversial)",
      "Neonatal alloimmune thrombocytopenia",
    ],
    adverseEffects: [
      "Headache and aseptic meningitis",
      "Thrombosis and hyperviscosity (especially with risk factors or high dose)",
      "Acute kidney injury (risk with sucrose-stabilized products, dehydration, CKD)",
      "Hemolysis from donor anti-A/anti-B isoagglutinins",
      "Anaphylaxis in IgA-deficient patients with anti-IgA antibodies",
      "Volume overload and heart failure exacerbation",
    ],
    boardsPearls: [
      "Kawasaki disease = high-dose IVIG + aspirin — give within first 10 days of illness",
      "ITP: IVIG blocks Fc receptors on splenic macrophages → ↓ platelet destruction; faster than steroids alone",
      "Guillain-Barré after Campylobacter — IVIG or plasmapheresis for severe disease",
      "Replacement vs immunomodulation — same product, different diseases (CVID vs ITP)",
      "vs Rho(D) immune globulin (anti-D) — specific antibody for Rh sensitization prophylaxis, not pooled IVIG",
      "vs rituximab — IVIG is pooled polyclonal IgG; rituximab depletes B cells",
      "vs SCIG — subcutaneous route for maintenance IgG replacement in CVID",
      "Live vaccines deferred after IVIG (passive antibody may blunt response)",
    ],
  },
  {
    id: "dupilumab",
    name: "Dupilumab",
    aliases: ["dupilumab", "dipilumab", "dupixent"],
    drugClass: "Anti–IL-4 receptor α monoclonal antibody",
    mechanism:
      "Binds IL-4 receptor α subunit → blocks signaling of both IL-4 and IL-13 → ↓ type 2 (Th2) inflammation (↓ IgE, eosinophil recruitment, barrier dysfunction).",
    indications: [
      "Moderate-to-severe atopic dermatitis",
      "Moderate-to-severe asthma with type 2 inflammation (eosinophilic or OCS-dependent)",
      "Chronic rhinosinusitis with nasal polyps",
      "Eosinophilic esophagitis",
    ],
    adverseEffects: [
      "Conjunctivitis and keratitis",
      "Injection-site reactions",
      "Eosinophilia",
      "Facial redness or dermatitis (uncommon)",
      "Paradoxical asthma worsening if systemic steroids stopped abruptly",
    ],
    boardsPearls: [
      "IL-4Rα blocker — interrupts IL-4 and IL-13 (type 2 / Th2 pathway)",
      "Atopic triad: eczema, asthma, allergic rhinitis — targets shared type 2 inflammation",
      "Conjunctivitis is the classic non-infectious adverse effect",
      "Do not abruptly discontinue systemic corticosteroids in asthma when starting dupilumab",
      "Peds: approved for atopic dermatitis in young children (age threshold varies); same type 2 mechanism as adults",
    ],
  },
  {
    id: "adalimumab",
    name: "Adalimumab",
    aliases: ["adalimumab", "dalimumab", "humira"],
    drugClass: "Anti–TNF-α monoclonal antibody",
    mechanism:
      "Fully human monoclonal antibody that binds soluble and membrane-bound TNF-α → prevents TNF-α receptor interaction → ↓ pro-inflammatory cytokine signaling, leukocyte recruitment, and tissue destruction.",
    indications: [
      "Rheumatoid arthritis",
      "Psoriasis and psoriatic arthritis",
      "Ankylosing spondylitis",
      "Crohn disease and ulcerative colitis",
      "Hidradenitis suppurativa",
      "Noninfectious uveitis",
      "Juvenile idiopathic arthritis",
    ],
    adverseEffects: [
      "Serious infections (including reactivation of latent tuberculosis)",
      "Injection-site reactions",
      "Malignancy risk (lymphoma, skin cancer)",
      "Heart failure exacerbation",
      "Demyelinating disease (rare)",
      "Drug-induced lupus and positive ANA",
    ],
    boardsPearls: [
      "TNF-α inhibitor — screen for latent TB (PPD/IGRA) and treat before starting; avoid live vaccines",
      "Fully human mAb (vs chimeric infliximab) — lower infusion reaction risk; subcutaneous dosing",
      "Contraindicated in untreated TB and moderate-to-severe heart failure",
      "Paradoxical psoriasis and new-onset demyelination reported — stop if neurologic symptoms",
      "Peds: approved for JIA and pediatric Crohn disease; same TB screening and infection precautions as adults",
    ],
  },
  {
    id: "statins",
    name: "Statins",
    aliases: [
      "statin",
      "statins",
      "hmg-coa reductase inhibitor",
      "hmg-coa reductase inhibitors",
      "atorvastatin",
      "simvastatin",
      "rosuvastatin",
      "pravastatin",
      "lovastatin",
    ],
    drugClass: "HMG-CoA reductase inhibitor",
    mechanism:
      "Competitively inhibit HMG-CoA reductase → ↓ hepatic cholesterol synthesis → ↑ LDL receptor expression → ↓ plasma LDL-C.",
    indications: [
      "Hyperlipidemia and atherosclerotic cardiovascular disease prevention",
      "Post-MI secondary prevention (↓ mortality)",
      "Familial hypercholesterolemia",
    ],
    adverseEffects: [
      "Myopathy and rhabdomyolysis (especially with fibrates or CYP3A4 inhibitors)",
      "Hepatotoxicity (transaminitis)",
      "New-onset diabetes mellitus",
    ],
    boardsPearls: [
      "Inhibit rate-limiting step of cholesterol synthesis — first-line for LDL lowering",
      "Myopathy risk ↑ with gemfibrozil, macrolides, azole antifungals, and grapefruit",
      "Check CK if muscle pain; stop if rhabdomyolysis suspected",
      "Peds: familial hypercholesterolemia — statins used in children ≥8–10 years with lifestyle measures",
    ],
  },
  {
    id: "nitroglycerin",
    name: "Nitroglycerin",
    aliases: [
      "nitroglycerin",
      "nitroglycerine",
      "ntg",
      "glyceryl trinitrate",
      "nitro",
    ],
    drugClass: "Nitrate vasodilator",
    mechanism:
      "Converted to nitric oxide (NO) → activates guanylate cyclase → ↑ cGMP → venodilation (>> arteriolar) → ↓ preload and myocardial O₂ demand.",
    indications: [
      "Acute angina / chest pain",
      "Acute pulmonary edema (with preload reduction)",
      "Hypertensive emergency (selected cases)",
    ],
    adverseEffects: [
      "Headache, flushing, hypotension",
      "Reflex tachycardia",
      "Tolerance with continuous use (requires nitrate-free interval)",
      "Methemoglobinemia (high doses, rare)",
    ],
    boardsPearls: [
      "Venodilator → ↓ preload; cornerstone of angina relief",
      "Absolute contraindication with PDE-5 inhibitors (sildenafil) → life-threatening hypotension",
      "Tolerance develops — nitrate-free interval (e.g., remove patch overnight)",
      "Peds: same NO/cGMP mechanism; used rarely in pediatric pulmonary hypertension under specialist care",
    ],
  },
  {
    id: "spironolactone",
    name: "Spironolactone",
    aliases: ["spironolactone", "aldactone"],
    drugClass: "Potassium-sparing diuretic / mineralocorticoid receptor antagonist (MRA)",
    mechanism:
      "Competitive aldosterone antagonist at mineralocorticoid receptor in collecting duct → ↓ Na⁺ reabsorption and ↓ K⁺/H⁺ secretion; also blocks androgen receptors (antiandrogenic effects).",
    indications: [
      "Heart failure with reduced ejection fraction (↓ mortality with ACE-I/β-blocker)",
      "Primary hyperaldosteronism",
      "Ascites in cirrhosis",
      "Resistant hypertension",
      "Hirsutism / acne (off-label antiandrogen)",
    ],
    adverseEffects: [
      "Hyperkalemia (especially with ACE-I/ARBs or renal insufficiency)",
      "Gynecomastia and breast tenderness (antiandrogenic)",
      "Menstrual irregularities",
      "Metabolic acidosis (type 4 RTA pattern)",
    ],
    boardsPearls: [
      "MRA — mortality benefit in HFrEF (RALES trial); hyperkalemia is main risk",
      "Avoid with eGFR <30 or K⁺ >5.0 unless closely monitored",
      "Eplerenone is more selective MRA with less gynecomastia",
      "Peds: hyperkalemia risk same; used in pediatric heart failure and hyperaldosteronism with monitoring",
    ],
  },
  {
    id: "hydrochlorothiazide",
    name: "Hydrochlorothiazide",
    aliases: [
      "hydrochlorothiazide",
      "hctz",
      "microzide",
      "thiazide diuretic",
      "thiazide diuretics",
    ],
    drugClass: "Thiazide diuretic",
    mechanism:
      "Inhibits NaCl cotransporter (NCC) in distal convoluted tubule → ↓ Na⁺ reabsorption → mild natriuresis and diuresis; also causes vasodilation with chronic use.",
    indications: [
      "Hypertension (first-line)",
      "Mild edema",
      "Nephrogenic diabetes insipidus (paradoxical antidiuretic effect)",
      "Calcium nephrolithiasis prophylaxis (↓ urinary Ca²⁺)",
    ],
    adverseEffects: [
      "Hypokalemia, hyponatremia, metabolic alkalosis",
      "Hyperuricemia / gout flares",
      "Hyperglycemia, hyperlipidemia",
      "Photosensitivity",
      "Sulfa allergy cross-reactivity (debated)",
    ],
    boardsPearls: [
      "First-line HTN agent — ineffective if GFR <30 (use loop diuretic instead)",
      "Hyponatremia especially in elderly — SIADH-like effect",
      "Thiazides ↓ Ca²⁺ excretion (vs loop diuretics which ↑ Ca²⁺ loss)",
      "Peds: used in pediatric HTN; same electrolyte monitoring; avoid in infants with hyperbilirubinemia (kernicterus risk with sulfonamides)",
    ],
  },
  {
    id: "losartan",
    name: "Losartan",
    aliases: [
      "losartan",
      "cozaar",
      "arb",
      "arbs",
      "angiotensin receptor blocker",
      "angiotensin receptor blockers",
      "angiotensin ii receptor blocker",
    ],
    drugClass: "Angiotensin II receptor blocker (ARB)",
    mechanism:
      "Selectively blocks AT₁ receptors → ↓ vasoconstriction, aldosterone release, and sympathetic activation without inhibiting kininase II (no bradykinin accumulation).",
    indications: [
      "Hypertension",
      "Heart failure (intolerant of ACE inhibitor cough)",
      "Diabetic nephropathy",
      "Post-MI LV dysfunction",
    ],
    adverseEffects: [
      "Hyperkalemia",
      "Teratogenic — contraindicated in pregnancy",
      "↑ creatinine / bilateral RAS can precipitate renal failure",
      "Dizziness, hypotension",
    ],
    boardsPearls: [
      "ARB — no dry cough (unlike ACE inhibitors); otherwise similar renal/vascular effects",
      "Contraindicated in pregnancy and bilateral renal artery stenosis",
      "Do not combine ACE-I + ARB routinely (↑ adverse effects without benefit)",
      "Peds: used in pediatric HTN and proteinuric kidney disease; same pregnancy contraindication",
    ],
  },
  {
    id: "epinephrine",
    name: "Epinephrine",
    aliases: ["epinephrine", "adrenaline", "epi"],
    drugClass: "Catecholamine (nonselective adrenergic agonist)",
    mechanism:
      "Agonist at α₁ (vasoconstriction), β₁ (↑ HR, contractility), and β₂ (bronchodilation, vasodilation in skeletal muscle) receptors; low-dose β₂ predominance, high-dose α₁ predominance.",
    indications: [
      "Anaphylaxis (IM first-line)",
      "Cardiac arrest (ACLS)",
      "Severe bronchospasm / asthma exacerbation",
      "Local vasoconstriction with anesthetics",
    ],
    adverseEffects: [
      "Tachycardia, arrhythmias, hypertension",
      "Anxiety, tremor, headache",
      "Tissue necrosis if extravasation (IV peripheral)",
      "Myocardial ischemia in susceptible patients",
    ],
    boardsPearls: [
      "Anaphylaxis: IM epinephrine into anterolateral thigh — not antihistamines alone",
      "β-blockers blunt β-mediated bronchodilation — may need glucagon if refractory anaphylaxis on β-blocker",
      "Low dose: β₂ > α₁; high dose: α₁ vasoconstriction dominates",
      "Peds: weight-based IM dosing (0.01 mg/kg); same first-line role in anaphylaxis",
    ],
  },
  {
    id: "allopurinol",
    name: "Allopurinol",
    aliases: ["allopurinol", "zyloprim"],
    drugClass: "Xanthine oxidase inhibitor",
    mechanism:
      "Inhibits xanthine oxidase → ↓ uric acid production from purine metabolism → ↓ serum urate.",
    indications: [
      "Chronic gout (urate-lowering therapy)",
      "Tumor lysis syndrome prophylaxis",
      "Recurrent calcium oxalate stones with hyperuricosuria",
    ],
    adverseEffects: [
      "Hypersensitivity syndrome (DRESS, SJS/TEN — especially with HLA-B*5801)",
      "Acute gout flare when initiating (start colchicine/NSAID prophylaxis)",
      "Hepatotoxicity, cytopenias (rare)",
      "↑ azathioprine/6-MP toxicity (shared xanthine oxidase pathway)",
    ],
    boardsPearls: [
      "Urate-lowering therapy — does not treat acute flare; may precipitate flare on initiation",
      "Always start flare prophylaxis (colchicine, NSAID, or steroid) when initiating",
      "Contraindicated with concurrent azathioprine or 6-mercaptopurine — fatal myelosuppression",
      "Febuxostat is alternative xanthine oxidase inhibitor",
      "Peds: tumor lysis prophylaxis in chemotherapy; same azathioprine interaction",
    ],
  },
  {
    id: "n-acetylcysteine",
    name: "N-Acetylcysteine",
    aliases: [
      "n-acetylcysteine",
      "nac",
      "acetylcysteine",
      "mucomyst",
    ],
    drugClass: "Glutathione precursor / mucolytic",
    mechanism:
      "Replenishes hepatic glutathione stores → detoxifies NAPQI (toxic acetaminophen metabolite); also mucolytic via free sulfhydryl groups breaking disulfide bonds in mucus.",
    indications: [
      "Acetaminophen overdose (antidote)",
      "Mucolytic (inhaled/oral for thick secretions)",
    ],
    adverseEffects: [
      "Nausea, vomiting (oral loading dose)",
      "Anaphylactoid reaction (IV formulation — histamine release)",
      "Bronchospasm (inhaled)",
    ],
    boardsPearls: [
      "Acetaminophen overdose antidote — most effective within 8–10 h of ingestion",
      "Rumack-Matthew nomogram guides treatment; give NAC if above treatment line",
      "Replenishes glutathione to conjugate NAPQI before hepatocyte necrosis",
      "Peds: weight-based NAC protocol; same nomogram principles",
    ],
  },
  {
    id: "phenytoin",
    name: "Phenytoin",
    aliases: ["phenytoin", "dilantin"],
    drugClass: "Antiepileptic (hydantoin)",
    mechanism:
      "Blocks voltage-gated Na⁺ channels by preferentially binding inactivated channels → ↓ neuronal firing and spread of seizure activity.",
    indications: [
      "Focal (partial) seizures",
      "Generalized tonic-clonic seizures",
      "Status epilepticus (IV fosphenytoin/phenytoin)",
      "Trigeminal neuralgia",
    ],
    adverseEffects: [
      "Gingival hyperplasia, hirsutism, coarsened facies",
      "Ataxia, nystagmus, cognitive slowing",
      "Megaloblastic anemia (↓ folate)",
      "SJS/TEN, drug-induced lupus",
      "Teratogenic (fetal hydantoin syndrome)",
    ],
    boardsPearls: [
      "Zero-order (saturable) kinetics — small dose ↑ can cause large level jump and toxicity",
      "Potent CYP450 inducer → many drug interactions (OCPs, warfarin, other AEDs)",
      "Monitor free phenytoin in hypoalbuminemia or uremia",
      "Peds: same zero-order kinetics; fetal hydantoin syndrome if exposed in utero",
    ],
  },
  {
    id: "carbamazepine",
    name: "Carbamazepine",
    aliases: ["carbamazepine", "tegretol"],
    drugClass: "Antiepileptic / mood stabilizer",
    mechanism:
      "Blocks voltage-gated Na⁺ channels → ↓ high-frequency neuronal firing; also potentiates GABAergic transmission.",
    indications: [
      "Focal seizures",
      "Trigeminal neuralgia",
      "Bipolar disorder (mood stabilization)",
    ],
    adverseEffects: [
      "Diplopia, ataxia, sedation",
      "Agranulocytosis, aplastic anemia (rare)",
      "SIADH → hyponatremia",
      "SJS/TEN (especially with HLA-B*1502 in Asian populations)",
      "Teratogenic (neural tube defects with valproate-like risk lower but still teratogenic)",
    ],
    boardsPearls: [
      "Induces its own metabolism and other CYP enzymes — autoinduction and drug interactions",
      "SIADH/hyponatremia is classic adverse effect — check sodium",
      "Screen HLA-B*1502 in at-risk Asian patients before starting (SJS risk)",
      "Peds: used for focal seizures and trigeminal neuralgia; same HLA screening in at-risk populations",
    ],
  },
  {
    id: "ethosuximide",
    name: "Ethosuximide",
    aliases: ["ethosuximide", "zarontin"],
    drugClass: "Antiepileptic (succinimide)",
    mechanism:
      "Blocks T-type Ca²⁺ channels in thalamic neurons → ↓ rhythmic burst firing underlying absence seizures.",
    indications: [
      "Absence seizures (childhood absence epilepsy)",
    ],
    adverseEffects: [
      "GI upset, nausea",
      "Drowsiness, headache",
      "Stevens-Johnson syndrome (rare)",
      "Blood dyscrasias (rare)",
    ],
    boardsPearls: [
      "First-line for absence seizures — targets T-type Ca²⁺ channels in thalamus",
      "Does not treat focal or tonic-clonic seizures — may worsen generalized tonic-clonic if used alone",
      "Classic 3-Hz spike-and-wave on EEG during absence seizure",
      "Peds: drug of choice for childhood absence epilepsy",
    ],
  },
  {
    id: "valproic-acid",
    name: "Valproic Acid",
    aliases: [
      "valproic acid",
      "valproate",
      "sodium valproate",
      "depakote",
      "depakene",
    ],
    drugClass: "Antiepileptic / mood stabilizer",
    mechanism:
      "Multiple mechanisms: ↑ GABA concentration, blocks Na⁺ channels, blocks T-type Ca²⁺ channels → broad-spectrum anticonvulsant.",
    indications: [
      "Generalized seizures (tonic-clonic, absence, myoclonic)",
      "Bipolar disorder (mood stabilization)",
      "Migraine prophylaxis",
    ],
    adverseEffects: [
      "Hepatotoxicity (especially children <2 on polytherapy)",
      "Teratogenic — neural tube defects, cognitive impairment (highest risk among AEDs)",
      "Pancreatitis",
      "Weight gain, hair loss, tremor",
      "Thrombocytopenia, hyperammonemia",
    ],
    boardsPearls: [
      "Broad-spectrum AED — treats most seizure types including absence and myoclonic",
      "Most teratogenic AED — avoid in women of childbearing potential if possible",
      "Inhibits CYP and glucuronidation → many drug interactions",
      "Monitor LFTs, platelets, and ammonia if encephalopathy",
      "Peds: ↑ hepatotoxicity risk in young children; still used for generalized epilepsy",
    ],
  },
  {
    id: "levodopa",
    name: "Levodopa",
    aliases: [
      "levodopa",
      "l-dopa",
      "l dopa",
      "carbidopa-levodopa",
      "sinemet",
    ],
    drugClass: "Dopamine precursor (antiparkinsonian)",
    mechanism:
      "Levodopa crosses blood-brain barrier → converted to dopamine in CNS → restores striatal dopamine; carbidopa (peripheral DOPA decarboxylase inhibitor) prevents peripheral conversion and ↑ CNS bioavailability.",
    indications: [
      "Parkinson disease (symptomatic treatment)",
      "Parkinsonism",
    ],
    adverseEffects: [
      "Motor fluctuations and dyskinesias (long-term)",
      "Nausea, vomiting, orthostatic hypotension",
      "Hallucinations and psychosis",
      "On-off phenomenon",
    ],
    boardsPearls: [
      "Gold standard for Parkinson motor symptoms — dopamine cannot cross BBB directly",
      "Carbidopa prevents peripheral decarboxylation (↓ nausea, ↑ CNS levodopa)",
      "Vitamin B6 reverses carbidopa effect — avoid supplementation",
      "Peds: rarely used; juvenile parkinsonism is uncommon — dopamine deficiency mechanism same",
    ],
  },
  {
    id: "lithium",
    name: "Lithium",
    aliases: ["lithium", "lithium carbonate", "lithobid"],
    drugClass: "Mood stabilizer",
    mechanism:
      "Inhibits inositol monophosphatase and glycogen synthase kinase-3 → alters second-messenger signaling; exact mood-stabilizing mechanism incompletely defined.",
    indications: [
      "Bipolar disorder (acute mania and maintenance)",
      "Augmentation in treatment-resistant depression",
    ],
    adverseEffects: [
      "Nephrogenic diabetes insipidus (↓ ADH responsiveness)",
      "Hypothyroidism and goiter",
      "Tremor, ataxia, confusion (toxicity)",
      "Teratogenic — Ebstein anomaly (cardiac malformation)",
      "Narrow therapeutic window — toxicity causes coarse tremor, confusion, seizures",
    ],
    boardsPearls: [
      "Narrow therapeutic index — monitor serum levels (0.6–1.2 mEq/L maintenance)",
      "Renally cleared — dose adjust in CKD; NSAIDs and ACE-I ↑ levels",
      "Nephrogenic DI — polyuria and polydipsia; responds to amiloride",
      "Peds: used in adolescent bipolar disorder; same Ebstein anomaly teratogenicity",
    ],
  },
  {
    id: "omeprazole",
    name: "Omeprazole",
    aliases: [
      "omeprazole",
      "prilosec",
      "ppi",
      "ppis",
      "proton pump inhibitor",
      "proton pump inhibitors",
    ],
    drugClass: "Proton pump inhibitor (PPI)",
    mechanism:
      "Irreversibly inhibits H⁺/K⁺-ATPase (proton pump) in gastric parietal cells → ↓ gastric acid secretion.",
    indications: [
      "GERD and erosive esophagitis",
      "Peptic ulcer disease",
      "H. pylori eradication (triple/quadruple therapy)",
      "Zollinger-Ellison syndrome",
    ],
    adverseEffects: [
      "Headache, diarrhea, abdominal pain",
      "↑ C. difficile infection risk",
      "Hypomagnesemia and B12 deficiency (chronic use)",
      "↑ fracture risk (chronic use — debated)",
    ],
    boardsPearls: [
      "Irreversible proton pump blockade — acid suppression lasts until new pumps synthesized",
      "CYP2C19 inhibitor — may ↓ clopidogrel activation (clinical significance debated)",
      "Take before meals for maximal effect",
      "Peds: used for GERD and eosinophilic esophagitis; same C. diff risk with prolonged use",
    ],
  },
  {
    id: "amoxicillin",
    name: "Amoxicillin",
    aliases: [
      "amoxicillin",
      "amoxil",
      "penicillin",
      "penicillins",
      "aminopenicillin",
    ],
    drugClass: "Aminopenicillin (β-lactam)",
    mechanism:
      "Binds penicillin-binding proteins (PBPs) → inhibits transpeptidase cross-linking of peptidoglycan → bactericidal cell wall disruption.",
    indications: [
      "Otitis media, sinusitis, streptococcal pharyngitis",
      "Community-acquired pneumonia (with macrolide or doxycycline)",
      "H. pylori eradication",
      "Lyme disease (early localized)",
      "Endocarditis prophylaxis (selected dental procedures)",
    ],
    adverseEffects: [
      "Hypersensitivity reactions (rash, anaphylaxis)",
      "Diarrhea (including C. difficile)",
      "Interstitial nephritis (rare)",
    ],
    boardsPearls: [
      "β-lactam — time-dependent killing; add clavulanate for β-lactamase producers",
      "Rash with amoxicillin common in EBV (infectious mononucleosis) — not always true allergy",
      "Methicillin-sensitive Staph aureus and Strep are covered; MRSA and atypicals are not",
      "Peds: first-line for otitis media and strep pharyngitis; weight-based dosing",
    ],
  },
  {
    id: "cephalosporins",
    name: "Cephalosporins",
    aliases: [
      "cephalosporin",
      "cephalosporins",
      "cefazolin",
      "ceftriaxone",
      "cefepime",
      "cefotaxime",
      "ceftazidime",
    ],
    drugClass: "β-lactam antibiotic (cephalosporin)",
    mechanism:
      "Bind PBPs and inhibit peptidoglycan cross-linking → bactericidal; generations differ in Gram-negative vs Gram-positive spectrum and β-lactamase stability.",
    indications: [
      "Skin/soft tissue, respiratory, urinary, and bloodstream infections (generation-dependent)",
      "Surgical prophylaxis (cefazolin)",
      "Meningitis (ceftriaxone/cefotaxime)",
      "Pseudomonas infections (ceftazidime, cefepime)",
    ],
    adverseEffects: [
      "Hypersensitivity (cross-reactivity with penicillins ~1–2% for anaphylaxis)",
      "Diarrhea, C. difficile colitis",
      "Ceftriaxone: biliary sludging, displace bilirubin from albumin (kernicterus risk in neonates)",
    ],
    boardsPearls: [
      "1st gen (cefazolin): Gram+ cocci; 3rd gen (ceftriaxone): broad Gram−, crosses BBB; 4th/5th gen: Pseudomonas coverage",
      "~1–2% cross-reactivity with penicillin anaphylaxis — higher cross-reactivity if similar R-group",
      "Ceftriaxone displaces bilirubin — avoid in hyperbilirubinemic neonates",
      "Peds: ceftriaxone for meningitis and serious infections; kernicterus caution in neonates",
    ],
  },
  {
    id: "metronidazole",
    name: "Metronidazole",
    aliases: ["metronidazole", "flagyl"],
    drugClass: "Nitroimidazole antibiotic / antiprotozoal",
    mechanism:
      "Reduced nitro group forms toxic free radicals → DNA strand breakage → bactericidal against anaerobes and antiprotozoal activity.",
    indications: [
      "Anaerobic infections (Bacteroides, Clostridium, intra-abdominal abscess)",
      "C. difficile colitis (oral)",
      "Trichomoniasis, giardiasis, amebiasis",
      "Bacterial vaginosis",
      "H. pylori eradication",
    ],
    adverseEffects: [
      "Metallic taste, nausea, disulfiram-like reaction with alcohol",
      "Peripheral neuropathy (prolonged use)",
      "Dark urine (benign metabolite)",
    ],
    boardsPearls: [
      "Covers anaerobes below diaphragm — classic with fluoroquinolone for diverticulitis",
      "Disulfiram-like reaction with alcohol — counsel patients",
      "Oral formulation treats C. difficile (not IV — IV does not reach colonic lumen)",
      "Peds: used for giardiasis and anaerobic infections; same alcohol interaction",
    ],
  },
  {
    id: "azithromycin",
    name: "Azithromycin",
    aliases: [
      "azithromycin",
      "zithromax",
      "z-pack",
      "macrolide",
      "macrolides",
      "erythromycin",
      "clarithromycin",
    ],
    drugClass: "Macrolide antibiotic",
    mechanism:
      "Binds 50S ribosomal subunit → blocks translocation → bacteriostatic; also inhibits CYP3A4 (especially erythromycin and clarithromycin).",
    indications: [
      "Community-acquired pneumonia (atypical coverage: Mycoplasma, Chlamydia, Legionella)",
      "Strep pharyngitis (penicillin allergy)",
      "MAC prophylaxis and treatment (with ethambutol)",
      "Chlamydia trachomatis",
    ],
    adverseEffects: [
      "GI upset (erythromycin worst; azithromycin better tolerated)",
      "QT prolongation → torsades de pointes",
      "Cholestatic hepatitis (especially erythromycin estolate)",
      "Acute generalized exanthematous pustulosis (rare)",
    ],
    boardsPearls: [
      "Atypical pneumonia coverage — Mycoplasma, Chlamydia, Legionella",
      "QT prolongation — avoid with other QT-prolonging drugs and in congenital long QT",
      "Azithromycin has minimal CYP inhibition vs clarithromycin/erythromycin",
      "Peds: azithromycin for otitis media and atypical pneumonia; same QT caution",
    ],
  },
  {
    id: "ciprofloxacin",
    name: "Ciprofloxacin",
    aliases: [
      "ciprofloxacin",
      "cipro",
      "fluoroquinolone",
      "fluoroquinolones",
      "levofloxacin",
      "moxifloxacin",
    ],
    drugClass: "Fluoroquinolone antibiotic",
    mechanism:
      "Inhibits DNA gyrase (topoisomerase II) and topoisomerase IV → prevents DNA supercoiling and replication → bactericidal.",
    indications: [
      "Complicated urinary tract infections and pyelonephritis",
      "Prostatitis",
      "GI infections (Salmonella, Shigella, travelers' diarrhea)",
      "Bone/joint infections (selected cases)",
      "Pseudomonas aeruginosa infections",
    ],
    adverseEffects: [
      "Tendon rupture (especially Achilles; ↑ risk with steroids)",
      "QT prolongation",
      "CNS effects (seizures, confusion — especially with NSAIDs/theophylline)",
      "Cartilage damage in children (avoid in growing patients)",
      "Glucose dysregulation (hypo- and hyperglycemia)",
    ],
    boardsPearls: [
      "DNA gyrase inhibitor — excellent Gram-negative coverage including Pseudomonas",
      "Avoid in children and pregnancy (cartilage toxicity)",
      "Tendon rupture — avoid in athletes and with concurrent corticosteroids",
      "Ciprofloxacin chelates cations (Ca²⁺, Fe²⁺) — ↓ absorption if taken together",
      "Peds: generally avoided due to cartilage toxicity; reserved for serious multidrug-resistant infections",
    ],
  },
  {
    id: "doxycycline",
    name: "Doxycycline",
    aliases: ["doxycycline", "vibramycin", "doryx"],
    drugClass: "Tetracycline antibiotic",
    mechanism:
      "Binds 30S ribosomal subunit → blocks aminoacyl-tRNA attachment → bacteriostatic; also inhibits matrix metalloproteinases.",
    indications: [
      "Atypical pneumonia (Mycoplasma, Chlamydia)",
      "Lyme disease, Rocky Mountain spotted fever, ehrlichiosis",
      "Acne vulgaris",
      "Malaria prophylaxis",
      "Chlamydia, rickettsial diseases",
    ],
    adverseEffects: [
      "Photosensitivity",
      "GI upset, esophageal ulceration (take upright with water)",
      "Teeth discoloration and enamel hypoplasia in children",
      "Inhibited bone growth in children",
      "Pseudotumor cerebri (benign intracranial hypertension)",
    ],
    boardsPearls: [
      "Contraindicated in pregnancy and children <8 (teeth discoloration, bone growth inhibition)",
      "First-line for Lyme disease, RMSF, and atypical pneumonia",
      "Photosensitivity — sun protection counseling",
      "vs minocycline — doxycycline less vestibular toxicity and pigmentation",
      "Peds: avoid <8 years; used for RMSF in children when benefit outweighs risk",
    ],
  },
  {
    id: "isoniazid",
    name: "Isoniazid",
    aliases: ["isoniazid", "inh"],
    drugClass: "Antitubercular agent",
    mechanism:
      "Inhibits mycolic acid synthesis (enoyl-ACP reductase/InhA pathway) → disrupts mycobacterial cell wall → bactericidal against actively dividing M. tuberculosis.",
    indications: [
      "Active tuberculosis (RIPE regimen)",
      "Latent tuberculosis infection (LTBI)",
    ],
    adverseEffects: [
      "Hepatotoxicity (monitor LFTs)",
      "Peripheral neuropathy (↓ pyridoxine/B6) — prevent with pyridoxine supplementation",
      "Drug-induced lupus (anti-histone antibodies)",
      "Seizures (especially with overdose or slow acetylators)",
    ],
    boardsPearls: [
      "RIPE: Rifampin, Isoniazid, Pyrazinamide, Ethambutol — first-line active TB",
      "Always give pyridoxine (vitamin B6) with INH to prevent neuropathy",
      "Hepatotoxicity — monitor transaminases; stop if symptomatic hepatitis",
      "Peds: same RIPE regimen; pyridoxine supplementation essential in children",
    ],
  },
  {
    id: "rifampin",
    name: "Rifampin",
    aliases: ["rifampin", "rifampicin", "rifadin"],
    drugClass: "Antitubercular agent / RNA polymerase inhibitor",
    mechanism:
      "Inhibits bacterial DNA-dependent RNA polymerase → blocks mRNA synthesis → bactericidal against M. tuberculosis and some Gram-positive organisms.",
    indications: [
      "Active tuberculosis (RIPE regimen)",
      "Latent TB (alternative regimen)",
      "Meningococcal and H. influenzae prophylaxis",
      "Staphylococcal prosthetic valve endocarditis (with β-lactam)",
    ],
    adverseEffects: [
      "Orange-red discoloration of body fluids (urine, tears, sweat)",
      "Hepatotoxicity",
      "Potent CYP450 inducer → many drug interactions (OCPs, warfarin, protease inhibitors)",
      "Flu-like syndrome (intermittent dosing)",
    ],
    boardsPearls: [
      "Potent CYP inducer — ↓ levels of many drugs including OCPs (pregnancy risk)",
      "Orange body fluids are harmless but classic boards detail",
      "Part of RIPE for active TB; also used for latent TB (with INH or alone)",
      "Peds: same RIPE regimen; orange secretions; CYP induction affects pediatric drug levels too",
    ],
  },
  {
    id: "acyclovir",
    name: "Acyclovir",
    aliases: ["acyclovir", "acycloguanosine", "zovirax"],
    drugClass: "Antiviral (guanosine analog)",
    mechanism:
      "Phosphorylated by viral thymidine kinase (HSV/VZV) then cellular kinases → acyclovir triphosphate competitively inhibits viral DNA polymerase and causes chain termination.",
    indications: [
      "Herpes simplex virus (oral/genital mucocutaneous)",
      "Varicella-zoster virus (chickenpox, shingles)",
      "HSV encephalitis (IV)",
      "Herpes keratitis",
    ],
    adverseEffects: [
      "Nausea, headache",
      "Nephrotoxicity and crystalluria (IV — adequate hydration)",
      "Neurotoxicity (confusion, tremor — especially in renal failure)",
    ],
    boardsPearls: [
      "Requires viral thymidine kinase for activation — selective for HSV/VZV-infected cells",
      "IV acyclovir: hydrate well to prevent crystalline nephropathy",
      "Ganciclovir used for CMV (requires viral kinase UL97)",
      "Peds: oral acyclovir for varicella in immunocompromised or severe disease; weight-based IV dosing",
    ],
  },
  {
    id: "amphotericin-b",
    name: "Amphotericin B",
    aliases: [
      "amphotericin b",
      "amphotericin",
      "ambisome",
      "fungizone",
    ],
    drugClass: "Polyene antifungal",
    mechanism:
      "Binds ergosterol in fungal cell membrane → forms pores → leakage of intracellular contents → fungicidal.",
    indications: [
      "Severe systemic fungal infections (cryptococcal meningitis, invasive aspergillosis, mucormycosis)",
      "Empiric antifungal therapy in febrile neutropenia",
    ],
    adverseEffects: [
      "Nephrotoxicity (↓ GFR — hydrate and monitor)",
      "Hypokalemia and hypomagnesemia",
      "Infusion-related fever, chills, rigors (\"shake and bake\")",
      "Anemia",
    ],
    boardsPearls: [
      "Broadest antifungal spectrum — \"amphoterrible\" for side effects",
      "Nephrotoxicity and electrolyte wasting — supplement K⁺ and Mg²⁺",
      "Liposomal formulation (AmBisome) ↓ nephrotoxicity",
      "vs azoles — amphotericin B binds ergosterol; azoles inhibit ergosterol synthesis",
      "Peds: same nephrotoxicity; liposomal preferred in pediatric systemic mycoses",
    ],
  },
  {
    id: "albuterol",
    name: "Albuterol",
    aliases: [
      "albuterol",
      "salbutamol",
      "ventolin",
      "proventil",
      "short-acting beta agonist",
      "saba",
    ],
    drugClass: "Short-acting β₂-adrenergic agonist (SABA)",
    mechanism:
      "Selective β₂ receptor agonism → ↑ adenylyl cyclase → ↑ cAMP → bronchial smooth muscle relaxation and ↓ mast cell mediator release.",
    indications: [
      "Acute bronchospasm (asthma, COPD exacerbation)",
      "Exercise-induced bronchospasm prophylaxis",
      "Hyperkalemia (drives K⁺ intracellularly with insulin)",
    ],
    adverseEffects: [
      "Tremor, tachycardia, palpitations",
      "Hypokalemia",
      "Paradoxical bronchospasm (rare)",
    ],
    boardsPearls: [
      "First-line rescue inhaler for acute asthma — SABA",
      "β₂-selective but tachycardia still occurs at higher doses",
      "Overuse (≥2 canisters/year) signals poor control — step up controller therapy",
      "Peds: same rescue role; spacer device improves delivery in young children",
    ],
  },
  {
    id: "methimazole",
    name: "Methimazole",
    aliases: [
      "methimazole",
      "tapazole",
      "propylthiouracil",
      "ptu",
      "antithyroid drug",
      "antithyroid drugs",
    ],
    drugClass: "Antithyroid agent (thionamide)",
    mechanism:
      "Inhibits thyroid peroxidase → blocks iodine organification and coupling of iodotyrosines → ↓ T3/T4 synthesis.",
    indications: [
      "Hyperthyroidism (Graves disease)",
      "Thyroid storm (with β-blocker and iodine)",
      "Preparation for thyroidectomy or radioiodine",
    ],
    adverseEffects: [
      "Agranulocytosis (rare but serious — sore throat/fever → stop drug)",
      "Hepatotoxicity (PTU more hepatotoxic; methimazole more cholestatic)",
      "Teratogenic — aplasia cutis, choanal atresia (especially methimazole)",
      "Rash, arthralgias",
    ],
    boardsPearls: [
      "Inhibits thyroid hormone synthesis — does not block release of stored hormone (takes weeks)",
      "Agranulocytosis — counsel to report fever/sore throat immediately",
      "PTU preferred in first trimester pregnancy; methimazole in 2nd/3rd trimester",
      "β-blocker (propranolol) treats adrenergic symptoms while antithyroid drug takes effect",
      "Peds: Graves disease in adolescents — same agranulocytosis monitoring",
    ],
  },
  {
    id: "cyclophosphamide",
    name: "Cyclophosphamide",
    aliases: ["cyclophosphamide", "cytoxan"],
    drugClass: "Alkylating agent / immunosuppressant",
    mechanism:
      "Prodrug activated by hepatic CYP → phosphoramide mustard cross-links DNA → cell cycle–nonspecific cytotoxicity; also suppresses B and T lymphocytes.",
    indications: [
      "ANCA-associated vasculitis (induction with glucocorticoids)",
      "Severe lupus nephritis",
      "Rheumatoid arthritis (refractory)",
      "Lymphomas and solid tumors (oncology dosing)",
    ],
    adverseEffects: [
      "Hemorrhagic cystitis (acrolein metabolite — prevent with mesna and hydration)",
      "Myelosuppression",
      "Infertility and teratogenicity",
      "Bladder cancer (long-term)",
      "SIADH",
    ],
    boardsPearls: [
      "Hemorrhagic cystitis — mesna binds acrolein; maintain high urine output",
      "ANCA vasculitis induction — alternative to rituximab",
      "Teratogenic — contraception mandatory during and after therapy",
      "Peds: used in severe pediatric vasculitis and nephritis; same hemorrhagic cystitis prevention",
    ],
  },
  {
    id: "cyclosporine",
    name: "Cyclosporine",
    aliases: ["cyclosporine", "ciclosporin", "cyclosporin", "neoral", "sandimmune"],
    drugClass: "Calcineurin inhibitor (immunosuppressant)",
    mechanism:
      "Binds cyclophilin → inhibits calcineurin → blocks NFAT dephosphorylation → ↓ IL-2 transcription → ↓ T-cell activation.",
    indications: [
      "Solid organ transplant rejection prophylaxis",
      "Severe psoriasis and atopic dermatitis (systemic)",
      "Rheumatoid arthritis, uveitis (selected cases)",
    ],
    adverseEffects: [
      "Nephrotoxicity (vasoconstriction — dose-dependent)",
      "Hypertension, hyperlipidemia, gingival hyperplasia, hirsutism",
      "Neurotoxicity (tremor, PRES)",
      "Increased infection and malignancy risk",
    ],
    boardsPearls: [
      "Calcineurin inhibitor — same pathway as tacrolimus; binds cyclophilin (vs FKBP for tacrolimus)",
      "Nephrotoxicity is dose- and trough-level–dependent — monitor levels",
      "CYP3A4 substrate — many drug interactions (azole antifungals ↑ levels; rifampin ↓ levels)",
      "vs tacrolimus — cyclosporine causes more gingival hyperplasia and hirsutism",
      "Peds: pediatric transplant immunosuppression; growth and infection monitoring",
    ],
  },
  {
    id: "infliximab",
    name: "Infliximab",
    aliases: ["infliximab", "remicade"],
    drugClass: "Anti–TNF-α monoclonal antibody (chimeric)",
    mechanism:
      "Chimeric (mouse-human) monoclonal antibody against TNF-α → prevents TNF-α receptor binding → ↓ pro-inflammatory cytokine signaling.",
    indications: [
      "Crohn disease and ulcerative colitis",
      "Rheumatoid arthritis",
      "Psoriasis and psoriatic arthritis",
      "Ankylosing spondylitis",
    ],
    adverseEffects: [
      "Infusion reactions (more common than fully human adalimumab)",
      "Reactivation of latent tuberculosis",
      "Increased infection risk",
      "Drug-induced lupus, positive ANA",
      "Heart failure exacerbation",
    ],
    boardsPearls: [
      "Chimeric anti-TNF — screen for latent TB before starting; avoid live vaccines",
      "IV infusion — higher infusion reaction risk vs subcutaneous adalimumab",
      "Same class warnings as adalimumab: TB reactivation, HF, demyelination",
      "Peds: approved for pediatric Crohn disease and JIA; same TB screening required",
    ],
  },
  {
    id: "hydralazine",
    name: "Hydralazine",
    aliases: ["hydralazine", "apresoline"],
    drugClass: "Direct arteriolar vasodilator",
    mechanism:
      "↑ cGMP in vascular smooth muscle → arteriolar vasodilation → ↓ afterload; exact molecular target incompletely defined (may involve K⁺ channel opening).",
    indications: [
      "Hypertension (often with isosorbide dinitrate in heart failure)",
      "Heart failure with reduced ejection fraction (BiDil: hydralazine + isosorbide in African American patients)",
      "Hypertensive emergency in pregnancy (selected cases)",
    ],
    adverseEffects: [
      "Reflex tachycardia, fluid retention",
      "Drug-induced lupus (slow acetylators — positive ANA, anti-histone antibodies)",
      "Headache, flushing",
      "Hemolytic anemia (rare)",
    ],
    boardsPearls: [
      "Drug-induced lupus — anti-histone antibodies; usually reverses on discontinuation",
      "Slow acetylators (NAT2) at higher risk of lupus and toxicity",
      "Combine with β-blocker to blunt reflex tachycardia",
      "Peds: rarely used; same lupus risk in slow acetylators",
    ],
  },
  {
    id: "mannitol",
    name: "Mannitol",
    aliases: ["mannitol", "osmitrol"],
    drugClass: "Osmotic diuretic",
    mechanism:
      "Freely filtered at glomerulus, not reabsorbed → ↑ tubular osmolarity → holds water in lumen → osmotic diuresis; also draws water from brain and eye across BBB.",
    indications: [
      "Elevated intracranial pressure / cerebral edema",
      "Acute angle-closure glaucoma (before definitive treatment)",
      "Oliguric acute kidney injury (test of renal responsiveness)",
    ],
    adverseEffects: [
      "Volume overload and pulmonary edema (if osmotic effect draws fluid into intravascular space)",
      "Hyponatremia or hypernatremia (depending on water shifts)",
      "Rebound intracranial hypertension if BBB disrupted",
      "Acute kidney injury (especially if already oliguric)",
    ],
    boardsPearls: [
      "Osmotic diuretic — ↑ serum osmolality draws water from brain → ↓ ICP",
      "Contraindicated in anuria and active intracranial hemorrhage",
      "Rebound ICP elevation when mannitol crosses disrupted BBB",
      "Peds: used for elevated ICP in traumatic brain injury; same osmotic mechanism",
    ],
  },
  {
    id: "acetazolamide",
    name: "Acetazolamide",
    aliases: ["acetazolamide", "diamox"],
    drugClass: "Carbonic anhydrase inhibitor",
    mechanism:
      "Inhibits carbonic anhydrase in proximal tubule and elsewhere → ↓ HCO₃⁻ reabsorption → bicarbonaturia, diuresis, and metabolic acidosis.",
    indications: [
      "Open-angle glaucoma (↓ aqueous humor production)",
      "Acute mountain sickness prophylaxis and treatment",
      "Idiopathic intracranial hypertension (pseudotumor cerebri)",
      "Metabolic alkalosis (promotes bicarbonate excretion)",
      "Epilepsy (absence seizures — adjunct)",
    ],
    adverseEffects: [
      "Metabolic acidosis (hyperchloremic)",
      "Paresthesias, fatigue",
      "Hypokalemia",
      "Sulfa allergy cross-reactivity",
      "Kidney stones (calcium phosphate — alkaline urine)",
    ],
    boardsPearls: [
      "Carbonic anhydrase inhibitor — causes self-limited diuresis and metabolic acidosis",
      "Acute mountain sickness: acetazolamide accelerates acclimatization via bicarbonaturia",
      "Pseudotumor cerebri: ↓ CSF production",
      "Peds: used for infantile glaucoma and pseudotumor cerebri; same acidosis risk",
    ],
  },
  {
    id: "magnesium-sulfate",
    name: "Magnesium Sulfate",
    aliases: [
      "magnesium sulfate",
      "magnesium sulphate",
      "mgso4",
    ],
    drugClass: "Electrolyte / anticonvulsant / tocolytic",
    mechanism:
      "↑ Mg²⁺ concentration antagonizes Ca²⁺ influx at NMDA receptors and L-type channels → CNS depression, smooth muscle relaxation, and ↓ neuromuscular excitability.",
    indications: [
      "Eclampsia and severe preeclampsia (seizure prophylaxis and treatment)",
      "Torsades de pointes (IV magnesium)",
      "Asthma exacerbation (adjunct bronchodilator)",
      "Preterm labor tocolysis (selected cases)",
    ],
    adverseEffects: [
      "Flushing, warmth",
      "Hypotension, bradycardia",
      "Respiratory depression and loss of deep tendon reflexes (toxicity)",
      "Monitor: deep tendon reflexes, respiratory rate, urine output",
    ],
    boardsPearls: [
      "Eclampsia: magnesium sulfate is anticonvulsant of choice — not diazepam or phenytoin",
      "Toxicity: loss of DTRs → respiratory depression → cardiac arrest; antidote is calcium gluconate",
      "Torsades de pointes: IV magnesium regardless of serum Mg level",
      "Peds: same role in pediatric torsades; eclampsia is obstetric but mechanism applies to any age",
    ],
  },
  {
    id: "ondansetron",
    name: "Ondansetron",
    aliases: [
      "ondansetron",
      "zofran",
      "5-ht3 antagonist",
      "5-ht3 receptor antagonist",
    ],
    drugClass: "5-HT₃ receptor antagonist (antiemetic)",
    mechanism:
      "Selective 5-HT₃ receptor antagonist in CTZ and vagal afferents → ↓ vomiting reflex activation.",
    indications: [
      "Chemotherapy-induced nausea and vomiting",
      "Postoperative nausea and vomiting",
      "Hyperemesis gravidarum (selected cases)",
    ],
    adverseEffects: [
      "Headache, constipation",
      "QT prolongation (high doses)",
      "Serotonin syndrome (with other serotonergic drugs — rare)",
    ],
    boardsPearls: [
      "First-line for chemotherapy-induced emesis — blocks 5-HT₃ in CTZ",
      "QT prolongation at high doses — caution in congenital long QT",
      "vs metoclopramide — ondansetron is pure 5-HT₃ block without D₂ prokinetic effects",
      "Peds: used for chemotherapy and postoperative nausea; weight-based dosing",
    ],
  },
  {
    id: "chlorpheniramine",
    name: "Chlorpheniramine",
    aliases: [
      "chlorpheniramine",
      "chlorpheniramine maleate",
      "chlor-trimeton",
    ],
    drugClass: "First-generation H1 antihistamine",
    mechanism:
      "Competitive H1 receptor antagonist (inverse agonist) → blocks histamine-mediated vasodilation, pruritus, and bronchospasm; crosses blood-brain barrier.",
    indications: [
      "Allergic rhinitis and conjunctivitis",
      "Urticaria and pruritus",
      "Common cold symptoms (adjunct)",
    ],
    adverseEffects: [
      "Sedation and impaired cognition",
      "Anticholinergic effects (dry mouth, urinary retention, constipation, blurred vision)",
      "Paradoxical excitation in children (rare)",
    ],
    boardsPearls: [
      "First-generation H1 blocker — sedating; crosses BBB",
      "Anticholinergic burden — caution in elderly (Beers criteria) and BPH/glaucoma",
      "vs second-generation agents (loratadine) — more sedation and anticholinergic effects",
      "Peds: paradoxical hyperactivity possible; weight-based dosing; avoid in young children when safer alternatives exist",
    ],
  },
  {
    id: "diphenhydramine",
    name: "Diphenhydramine",
    aliases: [
      "diphenhydramine",
      "benadryl",
      "diphenhydramine hcl",
    ],
    drugClass: "First-generation H1 antihistamine",
    mechanism:
      "Competitive H1 receptor antagonist with significant antimuscarinic activity → blocks histamine effects and muscarinic receptors (sedation, anticholinergic toxidrome risk).",
    indications: [
      "Allergic reactions (adjunct — not first-line for anaphylaxis)",
      "Pruritus and urticaria",
      "Insomnia (OTC)",
      "Motion sickness",
      "Acute dystonic reactions (IV/IM — alternative to benztropine)",
    ],
    adverseEffects: [
      "Sedation, confusion (especially elderly)",
      "Anticholinergic toxidrome in overdose (dry skin, mydriasis, urinary retention, hyperthermia, delirium)",
      "Paradoxical excitation in children",
      "Local anesthetic properties at high concentrations",
    ],
    boardsPearls: [
      "Classic first-generation H1 blocker — also antimuscarinic; crosses BBB → sedation",
      "Anticholinergic overdose toxidrome: hot as a hare, dry as a bone, mad as a hatter, blind as a bat",
      "Physostigmine for pure anticholinergic CNS toxicity — contraindicated in TCA overdose",
      "Adjunct in anaphylaxis only — epinephrine IM is first-line",
      "Peds: accidental ingestion common; same anticholinergic toxidrome; paradoxical excitation possible",
    ],
  },
  {
    id: "hydroxyzine",
    name: "Hydroxyzine",
    aliases: [
      "hydroxyzine",
      "hydroxyzine hcl",
      "hydroxyzine pamoate",
      "atarax",
      "vistaril",
    ],
    drugClass: "First-generation H1 antihistamine",
    mechanism:
      "H1 receptor antagonist with CNS depressant and anticholinergic effects; active metabolite cetirizine retains H1 blockade with less sedation.",
    indications: [
      "Pruritus (atopic dermatitis, urticaria)",
      "Short-term anxiety",
      "Preoperative sedation",
      "Allergic rhinitis",
    ],
    adverseEffects: [
      "Sedation and cognitive impairment",
      "Anticholinergic effects",
      "QT prolongation (rare, dose-dependent)",
      "Dry mouth, headache",
    ],
    boardsPearls: [
      "First-generation H1 blocker also used for pruritus and short-term anxiety",
      "Metabolized to cetirizine — explains overlapping H1 activity",
      "Sedating — avoid driving; caution with other CNS depressants",
      "Peds: used for atopic pruritus and pre-procedure sedation; weight-based dosing; sedation more pronounced than second-generation agents",
    ],
  },
  {
    id: "loratadine",
    name: "Loratadine",
    aliases: [
      "loratadine",
      "claritin",
      "second-generation antihistamine",
      "nonsedating antihistamine",
    ],
    drugClass: "Second-generation H1 antihistamine",
    mechanism:
      "Selective peripheral H1 receptor antagonist with minimal blood-brain barrier penetration → blocks histamine at H1 receptors without significant CNS sedation.",
    indications: [
      "Allergic rhinitis (seasonal and perennial)",
      "Chronic urticaria",
      "Allergic conjunctivitis",
    ],
    adverseEffects: [
      "Minimal sedation at standard doses",
      "Headache, fatigue (uncommon)",
      "Cardiac effects at supratherapeutic doses (rare — torsades)",
    ],
    boardsPearls: [
      "Second-generation H1 blocker — preferred for daytime use (less sedating than diphenhydramine)",
      "Active metabolite desloratadine — also available as separate drug",
      "Does not cross BBB well → ↓ sedation vs first-generation agents",
      "Peds: approved for allergic rhinitis/urticaria; preferred over sedating first-generation agents when alertness needed",
    ],
  },
  {
    id: "promethazine",
    name: "Promethazine",
    aliases: [
      "promethazine",
      "promethazine hcl",
      "phenergan",
    ],
    drugClass: "Phenothiazine derivative (H1 antihistamine / antiemetic)",
    mechanism:
      "H1 receptor antagonist with D₂ dopamine antagonism and anticholinergic activity → antiemetic (CTZ), sedative, and antihistamine effects.",
    indications: [
      "Nausea and vomiting",
      "Motion sickness",
      "Preoperative sedation",
      "Allergic symptoms (adjunct)",
    ],
    adverseEffects: [
      "Sedation, anticholinergic effects",
      "Extrapyramidal symptoms and dystonic reactions",
      "Respiratory depression — contraindicated in children <2 years (black box warning)",
      "Photosensitivity, hypotension (IV)",
      "Tissue injury with IV extravasation (highly irritant — give deep IM preferred)",
    ],
    boardsPearls: [
      "Phenothiazine with H1, D₂, and antimuscarinic activity — antiemetic and sedating antihistamine",
      "Black box: severe respiratory depression in young children — avoid <2 years",
      "vs ondansetron — promethazine is sedating with anticholinergic and EPS risk; ondansetron is 5-HT₃-specific",
      "IV extravasation causes severe tissue damage — prefer deep IM",
      "Peds: contraindicated <2 years; EPS/dystonia possible at any age — diphenhydramine treats acute dystonia",
    ],
  },
  {
    id: "vitamin-k",
    name: "Vitamin K",
    aliases: [
      "vitamin k",
      "phytonadione",
      "mephyton",
      "aquamephyton",
    ],
    drugClass: "Vitamin K (coagulation cofactor)",
    mechanism:
      "Essential cofactor for γ-carboxylation of glutamic acid residues on factors II, VII, IX, X and proteins C & S → enables calcium binding and coagulation cascade function.",
    indications: [
      "Warfarin reversal (serious bleeding or supratherapeutic INR)",
      "Vitamin K deficiency (malabsorption, prolonged antibiotics, newborn prophylaxis)",
      "Hemorrhagic disease of the newborn prophylaxis",
    ],
    adverseEffects: [
      "Anaphylaxis (IV administration — rare)",
      "Resistance to warfarin for several days after high-dose reversal",
    ],
    boardsPearls: [
      "Warfarin reversal: vitamin K for serious bleeding; FFP or PCC for emergent reversal",
      "IV vitamin K works in hours; oral takes 24 h; effect on INR peaks ~24 h",
      "Neonatal prophylaxis IM vitamin K prevents hemorrhagic disease of newborn",
      "Peds: all newborns receive vitamin K at birth — prevents VKDB",
    ],
  },
  {
    id: "dmards",
    name: "DMARDs",
    aliases: [
      "dmard",
      "dmards",
      "disease-modifying antirheumatic drug",
      "disease-modifying antirheumatic drugs",
      "disease modifying antirheumatic drug",
      "disease modifying antirheumatic drugs",
    ],
    drugClass: "Drug class",
    mechanism:
      "Slow or halt underlying autoimmune joint and tissue damage rather than only relieving symptoms; mechanisms vary by agent (antimetabolite, anti–TNF-α, calcineurin inhibition, antimalarial lysosomal effects, etc.).",
    indications: [
      "Rheumatoid arthritis (early initiation to prevent erosive disease)",
      "Psoriatic arthritis and ankylosing spondylitis",
      "Systemic lupus erythematosus (maintenance)",
      "Juvenile idiopathic arthritis",
    ],
    adverseEffects: [
      "Class-dependent — myelosuppression (methotrexate), hepatotoxicity, infection (biologics), retinopathy (hydroxychloroquine)",
      "Teratogenicity with several agents (methotrexate, leflunomide)",
    ],
    boardsPearls: [
      "Disease-modifying antirheumatic drugs — modify disease course, not just NSAID symptom control",
      "Methotrexate is anchor conventional synthetic DMARD in RA; biologic DMARDs (anti-TNF) for refractory disease",
      "Examples: methotrexate, hydroxychloroquine, sulfasalazine, leflunomide; biologics: adalimumab, infliximab, rituximab",
      "Start DMARDs early in RA — delays structural joint damage",
      "Peds: methotrexate anchor in JIA; biologics for refractory disease with TB screening before anti-TNF",
    ],
  },
];

const medicationById = new Map(MEDICATIONS.map((m) => [m.id, m]));

export function getMedicationById(id: string): MedicationEntry | undefined {
  return medicationById.get(id);
}

export interface MedicationAliasMatch {
  alias: string;
  medicationId: string;
}

export function buildMedicationAliasIndex(): MedicationAliasMatch[] {
  const matches: MedicationAliasMatch[] = [];
  for (const medication of MEDICATIONS) {
    for (const alias of medication.aliases) {
      matches.push({ alias: alias.toLowerCase(), medicationId: medication.id });
    }
  }
  return matches.sort((a, b) => b.alias.length - a.alias.length);
}
